United Cannabis (CNABQ) S-1 10 Sep 18 IPO registration Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	United Cannabis Corp
Entity Central Index Key	1,436,161
Document Type	S1
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 534,781	$ 825,645	$ 112,621
Inventory	1,644,216	43,200
Other current assets	24,372	23,028
Accounts receivable, net	41,877		24,484
Due from related parties	59,170		26,775
Total current assets	2,304,416	891,873	163,880
Construction in process - extraction facilities	185,699	832,697
Cultivation facility and laboratory equipment and office furniture and fixtures, net of accumulated amortization and depreciation of $39,385 and $0.0 at December 31, 2017 and December 31, 2016, respectively	1,748,172	199,821
Granted patents, net of accumulated amortization of $2,679 and $0.0 for December 31, 2017 and 2016, respectively	136,080	139,638
Intangible assets	259,568	170,519	32,273
Equity method investments			88,000
Goodwill	4,838,603	4,838,603
Total assets	9,472,538	7,073,151	284,153
Current liabilities:
Accounts payable	290,335	371,711	25,048
Accrued expenses	24,875	10,184	55,264
Installment loan payable	94,607	46,667
Current portion of deferred revenue	113,750	180,000	180,000
Accrued wages payable to officers, directors and employees	412,658	310,401	113,703
Notes payable to and advances from officers and directors	762,589	261,348	57,500
Convertible notes payable, net of a $34,543 debt discount	861,819		125,547
Arbitration settlement reserve	650,000
Total current liabilities	3,210,633	1,180,311	557,062
Long term liabilities:
Deferred revenue, net of current portion		23,750	203,750
Total liabilities	3,210,633	1,204,061	760,812
COMMITMENTS AND CONTINGENCIES - Note 19
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, 10,000,000 shares authorized; 2,000 Series A shares outstanding at June 30, 2018 and December 31, 2017, respectively and none outstanding at December 31, 2016	2,200	2,200
Common stock, 100,000,000 shares authorized; 64,229,926, 62,862,066 and 50,650,994 outstanding at June 30, 2018, December 31, 2017 and December 31, 2016, respectively	39,668,252	21,186,888	8,885,674
Accumulated deficit	(33,274,094)	(15,269,845)	(9,362,333)
Total equity (deficit) attributable to stockholders of the Company	6,396,358	5,919,243	(476,659)
Non-controlling interest (deficit)	(134,453)	(50,153)
Total stockholders' equity (deficit)	6,261,905	5,869,090	(476,659)
Total liabilities and stockholders' equity	$ 9,472,538	$ 7,073,151	$ 284,153

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Net of accumulated depreciation on facility	$ 191,897	$ 39,385	$ 0
Accumulated amortization on granted patents		2,679	0
Convertible notes payable, debt discount		$ 34,543	$ 34,543
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0	0
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued		62,862,066	50,650,994
Common stock, shares outstanding	64,229,926	62,862,066	50,650,994

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Product revenues	$ 1,762,495	$ 30,381	$ 1,926,707	$ 130,058
Licensing fees	57,288	45,000	102,288	90,000
Revenues, non-affiliates					$ 180,000	$ 695,095
Revenues, affiliate	42,039	88,752	99,103	133,752	182,323	20,000
Total revenues	1,861,822	164,133	2,128,098	353,810	362,323	715,095
Cost of revenues:
Cost of revenues, non-affiliate						(335,571)
Cost of revenues, affiliate					(134,795)	(7,500)
Total cost of revenues	(1,393,469)	(90,950)	(1,512,411)	(212,001)	(134,795)	(343,071)
Gross profit	468,353	73,183	615,687	141,809	227,528	372,024
Operating expenses:
Marketing, advertising and new business development	9,710	39,373	27,021	92,765	142,094	68,007
Research and development	241,547	4,235	478,225	49,395	293,968	23,124
Legal, accounting, consulting and public reporting	379,579	215,386	642,825	456,200	878,257	643,913
General and administrative	845,640	309,191	1,848,436	558,051	4,101,367	404,002
Fair market value of stock options granted to officers, directors and employees	9,403,271	1,624,000	14,728,025	1,624,000
Total operating expenses	10,879,747	2,192,185	17,724,532	2,780,411	5,415,686	1,139,046
Loss from operations	(10,411,394)	(2,119,002)	(17,108,845)	(2,638,602)	(5,188,158)	(767,022)
Other income (expense):
Other income and expenses						184,875
Loss on derivative liabilities						(1,894,258)
Interest expense	(42,605)	(18,864)	(51,103)	(47,673)	(61,534)	(418,437)
Amortization of debt discount						(267,258)
Loss on extinguishment of debt and repurchase of warrants				(267,567)	(248,892)	(691,904)
Loss on settlement of dispute		(122,139)		(122,139)	(122,139)
Loss on issuance of common stock	(372,540)		(928,601)		(582,881)
Loss before taxes on income	(10,826,539)	(2,260,005)	(18,088,549)	(3,075,981)	(6,203,604)	(3,854,004)
Provision for taxes on income
Net Loss	(10,826,539)	(2,260,005)	(18,088,549)	(3,075,981)	(6,203,604)	(3,854,004)
Loss attributable to non-controlling interests	28,849	161,232	84,299	161,232	296,092
Net Loss attributable to common shareholders	$ (10,797,690)	$ (2,098,773)	$ (18,004,250)	$ (2,914,749)	$ (5,907,512)	$ (3,854,004)
Basic loss per common share	$ (0.17)	$ (0.04)	$ (0.28)	$ (0.06)
Basic and diluted net loss per share:					$ (0.11)	$ (0.08)
Basic and diluted weighted-average common shares outstanding:	65,061,437	52,230,430	64,448,843	51,604,623	54,261,197	46,722,407

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Beginning balance at Dec. 31, 2015		$ 3,039,448	$ (5,508,329)		$ (2,468,881)
Beginning balance, shares at Dec. 31, 2015		44,988,501
Options issued to officers and directors for accrued wages		$ 612,512			612,512
Warrants issued for services		319,419			319,419
Stock options issued for compensation		$ 271,097			271,097
Stock options issued for compensation, shares		565,576
Shares issued for payables and accrued expenses		$ 223,484			223,484
Shares issued for payables and accrued expenses, shares		509,549
Conversion of note to Tangiers		$ 473,966			473,966
Conversion of note to Tangiers, shares		2,843,698
Conversion of notes payable		$ 3,845,748			3,845,748
Conversion of notes payable, shares		1,638,731
Share buy-back with exercise of put option		$ 100,000			100,000
Share buy-back with exercise of put option, shares		104,939
Shares issued for advisory board services
Shares issued in settlement of disputes
Net loss			(3,854,004)		(3,854,004)
Ending balance at Dec. 31, 2016		$ 8,885,674	(9,362,333)		(476,659)
Ending balance, shares at Dec. 31, 2016		50,650,994
Issuance of preferred stock	$ 2,200				2,200
Issuance of preferred stock, shares	2,000
Consolidation of Cannabinoid Research & Development Limited as a 50% variable interest entity				(18,872)	(18,872)
Consolidation of Cannabinoid Research & Development Limited as a 50% variable interest entity, shares
Options issued to officers and directors for accrued wages		2,660,159			2,660,159
Warrants issued for services					249,835
Stock options issued for compensation		$ 170,233			170,233
Stock options issued for compensation, shares		163,534
Shares issued for payables and accrued expenses		$ 93,002			93,002
Shares issued for payables and accrued expenses, shares		66,000
Conversion of notes payable		$ 381,576			381,576
Conversion of notes payable, shares		379,100
Shares issued for advisory board services		$ 113,336			113,336
Shares issued for advisory board services, shares		111,173
Shares issued for professional and consulting services		$ 249,833			249,833
Shares issued for professional and consulting services, shares		239,700
Shares issued in settlement of disputes		$ 102,139			102,139
Shares issued in settlement of disputes, shares		100,000
Sale of common stock		$ 208,982			208,982
Sale of common stock, shares		271,136
Shares issued upon draws under our equity line of credit		$ 3,228,954			3,228,954
Shares issued upon draws under our equity line of credit, shares		3,714,238
Shares issued to acquire Prana Therapeutics, Inc.		$ 4,870,500		264,811	5,135,311
Shares issued to acquire Prana Therapeutics, Inc., shares		5,730,000
Exercise of options and warrants		$ 222,500			222,500
Exercise of options and warrants, shares		1,436,191
Non-Controlling Interests - Cannabinoid Research & Development Limited.				(291,918)	(291,918)
Non-Controlling Interests - Cannabinoid Research & Development Limited., shares
Non-Controlling Interest - Prana Therapeutics, Inc.				(4,174)	(4,174)
Non-Controlling Interest - Prana Therapeutics, Inc., shares
Net loss			(5,907,512)		(5,907,512)
Ending balance at Dec. 31, 2017	$ 2,200	$ 21,186,888	$ (15,269,845)	$ (50,153)	5,869,090
Ending balance, shares at Dec. 31, 2017	2,000	62,862,066
Net loss					(18,004,250)
Ending balance at Jun. 30, 2018					$ 6,261,905

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (18,088,549)	$ (3,075,981)	$ (6,203,604)	$ (3,854,004)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Increase (decrease) in provision for losses on accounts receivable				(4,619)
Amortization of debt discount	16,819	34,453	30,453	267,258
Depreciation and amortization	156,098	12,079	40,161
Amortization of deferred financing costs				32,400
Loan origination discount				15,500
Share-based compensation, net	14,914,372	2,025,369	3,286,565	622,450
Discount on issuance of shares of common stock	928,601		582,881
Loss on settlement of dispute		102,139	122,139
Loss on revaluation of derivative liabilities				1,894,258
Loss on extinguishment of debt and repurchase of warrants		248,892	248,892	691,904
Loss on non-marketable equity securities				15,125
Abandonment of consulting project and resultant recognition of deferred revenue				(200,000)
Increase in net assets in connection with acquisition of fifty percent owned subsidiary		(37,546)
Changes in operating assets and liabilities:
Accounts receivable	(41,877)	24,484	24,484	33,570
Other current assets	(1,344)		(23,028)
Due from related party	(59,170)	19,584	26,775	(18,491)
Inventory	(1,601,016)		(43,200)
Prepaid expenses				56,341
Accounts payable and accrued expenses	(66,684)	44,096	(81,876)	239,935
Deferred revenue	(90,000)	(90,000)	(180,000)	(180,000)
Accrued wages payable to officers and directors	102,458	318,407	213,698	42,695
Notes payable to and advances from officers and directors			77,384	71,008
Net cash used in operating activities	(3,830,292)	(374,024)	(1,878,276)	(274,670)
Investing activities:
Cash acquired upon acquisition of subsidiary			363,134
Improvements to cultivation and extraction facilities and purchase of equipment	(977,179)	(246,283)	(621,731)
Purchase of intangible assets	(89,050)	(83,922)	(197,164)
Return of deposit		(32,500)	(32,500)
Cash portion of settlement of dispute			(20,000)
Purchase of non-marketable securities		(50,000)
Net cash provided by (used in) investing activities	(1,066,229)	(412,705)	(508,261)
Financing activities:
Proceeds from issuance of common stock - equity financing line	2,581,108	1,056,142	2,682,750
Proceeds from notes payable to and advances from officers and directors	501,241	245,286	254,942	50,000
Net proceeds from issuance of convertible debt and warrants	845,000			316,478
Proceeds from proposed joint venture that was never formed	650,000
Repayment of convertible debt and notes payable			(31,000)	(242,607)
Proceeds from issuance of common shares and exercise of warrants	57,083		192,869	145,000
Payments on installment loan	(28,775)	(35,000)
Net cash provided by (used in) financing activities	4,605,657	1,266,428	3,099,561	268,871
Net increase (decrease) in cash	(290,864)	479,699	713,024	(5,799)
Cash, beginning of period	825,645	112,621	112,621	118,420
Cash, end of period	534,781	592,320	825,645	112,621
Supplemental schedule of cash flow information:
Cash paid for interest				8,165
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Common shares issued in the acquisition of Prana Therapeutics, Inc.			4,870,500
Issuance of stock options in exchange for accrued wages payable to officers and directors				612,512
Common stock issued upon exercise of cashless warrants			350,000	700,000
Reduction of convertible notes payable due to the conversion by Tangiers Global				220,000
Issuance of common stock upon conversion of debt and loss on extinguishment of debt			381,576	473,965
Reduction of three convertible notes payable due to the conversion by Slainte Ventures				206,978
Issuance of common stock upon conversion of Slainte Ventures note payable				218,038
Reduction of note payable due to the conversion by Slainte Ventures				600,000
Issuance of common stock upon conversion of Slainte Ventures note payable				3,845,748
Reduction of notes payable in exchange for 1,100,000 shares of common stock of WeedMD				175,000
Acquisition of equipment from related party		57,909	99,200
Warrants cancelled				$ (3,000,000)
Subscription to purchase common stock of a related entity - Prana Therapeutics, Inc		150,000
Exercise of stock option for 1,000,000 of common stock in exchange for notes payable to an officer and director		$ 200,000

CONSOLIDATED STATEMENTS OF CAS7

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Statement of Cash Flows [Abstract]
Notes payable in exchange for shares of common stock	1,000,000	1,100,000

BUSINESS ORGANIZATION AND NATUR

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS United Cannabis Corporation ("we", "our", "us", "UCANN", or “the Company”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the prior President of the Company. In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry. On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock. In connection with this transaction: · Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry. · The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement. · Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014. · Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President. · A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014. UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation. On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we entered into a new business and no longer had any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. On July 14, 2017, we completed the acquisition of Prana Therapeutics, Inc. (“PTI”) by exchanging 5,730,000 shares of common stock of the Company for 5,730,000 shares of the common stock of PTI. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share on the OTC QB Market on July 14, 2017, including the cost to purchase 400,000 shares of PTI common stock for $200,000. PTI is a polymolecular botanical drug development company focused on developing targeted therapeutics for prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer. Management elected to purchase PTI, because of the successful indication of the effectiveness of their Epidiferphane™ chemical formulation in the treatment of (i) the negative side effects of chemotherapy, (ii) inflammation and pain associated with arthritis and back-centric pain, and (iii)the potential shrinkage of cancerous tumors. On August 3, 2018, PTI received notice that their licensed flagship product, EDP™, received approval on an Investigational New Drug application from the FDA for a clinical investigation for breast cancer. The clinical investigation will include a dose escalation, safety, tolerability, pharmacokinetic, and efficacy trial. Phase 1 will test the potential toxicity of EDP™ at two targeted dosages and measures safety levels, side effects, optimal dosage, and formulation. Phase 2 will focus on whether or not EDP™ passes efficacy evaluations by reducing side effects of chemotherapy in patients. Recently, we elected to focus a significant portion of our assets, human resources and financial capital on the manufacturing and selling of a variety of cannabidiol centric products derived from industrial hemp plants. We constructed a state-of-the-art extraction facility; and, hired and trained specialized extraction personnel and laboratory technicians that enable us to convert components of industrial hemp flower to finished CBD products. In order to help provide a consistent supply of industrial hemp flower for our extraction facility, we purchased farming equipment and leased hundreds of acres of farm land on which we are growing a crop of industrial hemp plants. It is our intent to grow at least one crop of industrial hemp plants per calendar year and to harvest a sufficient amount of industrial hemp flower from our crop to supply our extraction facility on a vertically integrated basis. As of June 30, 2018, we have expended approximately $2,800,000 on facilities, farm equipment and crop planting and cultivation, as a result of electing to vertically integrate the hemp centric portion of our business. Government Regulation	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS United Cannabis Corporation ("we", "our", "us", "UCANN", or “the Company”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the prior President of the Company. In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry. On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock. In connection with this transaction: · Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry. · The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement. · Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014. · Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President. · A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014. UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation. On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we entered into a new business and no longer had any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. On July 14, 2017, we completed the acquisition of Prana Therapeutics, Inc. (“Prana”) in a one-for-one exchange of 5,730,000 shares of common stock of the Company for 5,730,000 of common stock of Prana. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share on the OTC QB exchange on July 14, 2017, including the cost to purchase 400,000 shares of Prana common stock for $200,000. Prana is a polymolecular botanical drug development company focused on developing targeted therapeutics for prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer. Management elected to purchase Prana, because of the successful indication of the effectiveness of their Epidiferphane™ chemical formulation in the treatment of (i) the negative side effects of chemotherapy, (ii) inflammation and pain associated with arthritis and back-centric pain, (iii) sleep disorder, and (iv) the potential shrinkage of brain tumors. Government Regulation As of December 31, 2017, 30 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of California, Colorado, Washington, Nevada, Oregon, Alaska, Maine, Massachusetts, Vermont and the District of Columbia have approved ballot measures to legalize cannabis for adult recreational use. The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The former Obama administration had effectively stated that it was not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical and recreational marijuana under what colloquially became known as the “Cole memo”. However, on January 4, 2018, Attorney General Jeffery Sessions rescinded the “Cole memo,” and issued a new memo in its place that reaffirms the Department of Justice’s stance of potentially prosecuting violators of federal marijuana laws. If current administration elects to vigorously enforce federal laws, such enforcement may cause significant financial damage to us.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation At March 31, 2017, we concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017. PTI was purchased on July 14, 2017, and their assets and liabilities are included in the consolidated balance sheets at December 31, 2017, and their results of operations are included in the consolidated financial statements for the period of June 30, 2017, which is the nearest quarter end to the purchase date, through December 31, 2017. Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at June 30, 2018, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the six-month period ended June 30, 2018 and the year ended December 31, 2017. Cash and Cash Equivalents Accounts Receivable, Net Inventory – Property, Plant and Equipment, net Granted Patents. Net – Intangible Assets – Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of June 30, 2018 or December 31, 2017. Goodwill – Purchase Price Allocation – Business Combinations Fair Value Measurements and Disclosures Deferred Revenue Revenue Recognition Revenue from Contracts with Customers Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Revenue from Contracts with Customers. Cost of Revenues Research and Development Expenses General and Administrative Expenses Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the year ended year-ended December 31, 2017 or the six months ended June 30, 2018. Commitments and Contingencies – Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Warrants to purchase common stock 25,002 1,549,112 1,259,029 1,549,112 Stock options 13,250,000 3,680,000 25,080,000 6,580,000 13,275,002 5,229,112 26,339,029 8,129,112 Other Comprehensive Income (Loss) Concentration of Credit Risk Recently Issued Accounting Pronouncements In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures. Reclassification	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at December 31, 2016, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the years ended December 31, 2017 and 2016. Cash and Cash Equivalents Accounts Receivable Our allowance for doubtful accounts was $0.00 and $30,000 as of December 31, 2017 and 2016, respectively. We recorded bad debt expense, included in general and administrative expenses, of $0.00 and $82,831 during the years ended December 31, 2017 and 2016, respectively. Prepaid Expenses - Inventory – Property and Equipment December 31, 2017 2018 Conduction in process - extraction facilities Weldona, Colorado extraction facility: Equipment $ 647,947 $ — Leasehold improvements — — Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 — Leasehold improvements - cultivation 109,750 — $ 832,697 $ — Cultivation facility and laboratory equipment and Office furniture and fixtures Golden, Colorado hemp laboratory - equipment $ 34,651 — Golden, Colorado administrative offices: Furniture and fixtures 21,668 — Leasehold improvements 2,000 — Transportation equipment 81,667 — Remote laboratory equipment 99,220 — 239,206 — Accumulated amortization and depreciation (39,385 ) — $ 199,821 $ — Granted Patents – Intangible Assets – Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of December 31, 2017 or December 31, 2016. Equity Method Investments Goodwill Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures Deferred Revenue Revenue Recognition - Revenue Recognition Revenue for services with a payment in the form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue paid for with warrants is measured using the Black-Scholes-Merton pricing model. Revenue from product sales, including delivery fees, is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Reimbursable expenses, including those relating to travel, other out-of-pocket expenses and any third-party costs, are included as a component of revenues. Typically, an equivalent amount of reimbursable expenses is included in cost of revenues. Reimbursable expenses related to time and materials and fixed-fee engagements are recognized as revenue in the period in which the expense is incurred and collectability is reasonably assured. Taxes collected from customers and remitted to governmental authorities are presented in our consolidated statement of operations on a net basis. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Prana Revenue Recognition. Cost of Revenues Research and Development Expenses - General and Administrative Expenses - Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the year ended year-ended December 31, 2017. Commitments and Contingencies If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Years Ended December 31, 2017 2016 Warrants to purchase common stock 674,336 666,667 Cashless warrants exercisable and not converted to common stock 534,689 844,689 Stock options 6,637,500 3,680,000 Total potentially dilutive securities 7,846,525 5,191,356 Other Comprehensive Income (Loss) Segment Reporting – Concentration of Credit Risk The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Years Ended December 31, 2017 2016 Customer A 98 % 95 % Customer B 2 % 3 % Customer C — % 2 % Percentage of Accounts Receivable: Years Ended December 31, 2017 2016 Customer D — % 75 % Customer E — % 25 % Customer F 100 % — % Recently Issued Accounting Pronouncements In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five-step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective at the beginning of fiscal year 2018, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We implemented this accounting treatment beginning January 1, 2018. In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures.

GOING CONCERN

GOING CONCERN	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
GOING CONCERN [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the six-months ended June 30, 2018, we incurred losses of $18,088,549, used cash of $3,830,292 in our operating activities and had an accumulated deficit of $33,274,094 at June 30, 2018. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.	NOTE 3 – GOING CONCERN Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the year ended December 31, 2017, we incurred losses of $5,907,512 and used cash of $1,878,276 in our operating activities. As at December 31, 2017, we had a working capital deficit of $288,439 and an accumulated deficit of $15,269,845. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

RECEIVABLE FROM RELATED PARTY

RECEIVABLE FROM RELATED PARTY	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Receivable From Related Party
RECEIVABLE FROM RELATED PARTY	NOTE 4 – RECEIVABLE FROM RELATED PARTY In the normal course of business, we make non-interest-bearing advances to Advesa, Inc. (“Advesa’), which is controlled by one of our officers and directors, and we receive licensing fees from the sale of products licensed to Advesa by the Company. Related party amounts due from Advesa were $59,170 and $0 at June 30, 2018 and December 31, 2017, respectively.	NOTE 4 – RECEIVABLE FROM RELATED PARTY On April 20, 2015, we advanced Cannabinoid Research & Development, Limited (“CRD”) $5,000 and included this amount in due from related parties. At March 31, 2017, we concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017. Thus, at September 30, 2017, the $5,000 advance to CRD is eliminated upon the consolidation of the assets and liabilities of CRD for financial statement reporting purposes. In the normal course of business, we make non-interest-bearing advances to Advesa, Inc. (“Advesa’), which is 100% owned by one of our officers and directors. Such advances are used by Advesa to purchase equipment and to cover the cost of their operations. Additionally, during the year ended December 31, 2017, we purchased certain laboratory equipment from Advesa at an amount equal to their cost of the equipment. Amounts due from related parties consist of: December 31, 2017 2016 Advesa, Inc. $ — $ 21,775 Cannabinoid Research & Development, Limited — 5,000 $ — $ 26,775

OPERATING LEASES

OPERATING LEASES	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Operating Leases
OPERATING LEASES	NOTE 5 – OPERATING LEASES Administrative Offices and Industrial Hemp Laboratory – Golden, Colorado Effective August 1, 2017, we entered into a triple net lease for approximately 9,882 square feet of commercial space in Golden, Colorado in which our administrative offices and industrial hemp laboratory are located. The term of the lease expires on July 31, 2020 and has no option for renewal. Basic rent is $3,302, $3,500 and $3,800 per month through, July 31, 2018, 2019 and 2020, respectively, plus we are responsible for all utilities. Extraction and Cultivation Facility – Weldona, Colorado Effective October 1, 2017, we entered into a triple net lease for approximately 40,000 square feet of industrial space located on five (5) acres of land in Weldona, Colorado that we use as our industrial hemp extraction facility and industrial hemp cultivation center. The term of the lease expires on September 31, 2018, with an annual option to renew the lease on an annual basis, until September 30, 2022. The rent is $7,500 per month throughout the term of the lease, plus we are responsible for all utilities. Extraction and Cultivation Facility Jamaica Our fifty percent (50%) owned subsidiary Cannabinoid Research & Development Company Limited (“CRD”) leases approximately 28 acres of land upon which their cultivation and extraction facility is located near Kingston, Jamaica. The land is leased for $1 per year from the father of one of the directors and members of CRD. Future minimum payments for these leases are: For the twelve Months Ending June 30, 2019 2020 2021 2021 2022 $131,804 $135,296 $93,801 $90,001 $45,001	NOTE 5 – OPERATING LEASES Administrative Offices and Hemp Laboratory – Golden, Colorado Effective August 1, 2017, we entered into a triple net lease of approximately 9,882 square feet of commercial space in Golden, Colorado in which our administrative offices and hemp laboratory are located. The term of the lease expires on July 31, 2020 and has no option for renewal. Basic rent is $3,302, $3,500 and $3,800 per month through, July 31, 2018, 2019 and 2020, respectively, plus we are responsible for all utilities. It is our intent presently, to renew the lease annual throughout the term of the lease. Extraction and Cultivation Facility – Golden Colorado Effective October 1, 2017, we entered into a triple net lease of approximately 40,000 square feet of industrial space located on five (5) acres of land in Weldona, Colorado that we us as our hemp extraction facility and hemp cultivation center. The term of the lease expires on September 31, 2018, with an annual option to renew the lease on an annual basis, that expires on September 30, 2022. The rent is $7,500 per month throughout the term of the lease, plus we are responsible for all utilities. Extraction and Cultivation Facility - Jamaica Our fifty percent (50%) owned subsidiary Cannabinoid Research & Development Company Limited (“CRD”) leases approximately 28 acres of land upon which their cultivation and extraction facility is located near Kingston, Jamaica. The land is leased for $1 per year from the father of one of the directors and members of CRD. Future minimum payments for these leases are: For the twelve Months Ending December 31, 2018 2019 2020 2021 2022 $130,613 $133,499 $116,597 $90,000 $67,500

INVENTORY

INVENTORY	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Inventory Abstract
INVENTORY	NOTE 6 – INVENTORY At June 30, 2018 and December 31, 2017, our inventory is, as follows: June 30, December 31, 2018 2017 Industrial hemp crop under cultivation $ 1,391,306 $ 15,000 Raw materials 239,030 — Work-in-process — — Finished goods 13,880 28,200 $ 1,644,216 $ 43,200 We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of revenue sold. There have been no such write-downs during the six-month period ended June 30, 2018 and 2017.	NOTE 6 - INVENTORY Inventory is stated at the lower of cost or market. Cost is determined based upon the cost to acquire the raw materials, plus internal labor and other costs incurred to produce finished goods inventory. The cost of inventory is principally determined using the last-in first-out method. We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold. At December 31, 2017, and 2016, our inventory was, as follows: December 31, 2017 2016 Raw materials $ 15,000 $ — Work-in-process — — Finished goods 28,200 — $ 43,200 $ —

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment, Net [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 7 – PROPERTY, PLANT AND EQUIPMENT, NET June 30, December 31, 2018 2017 Cost of construction in process - extraction facility Weldona, Colorado extraction facility: Equipment $ — $ 647,947 Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 75,000 Leasehold improvements - cultivation 110,699 109,750 $ 185,699 $ 832,697 Extraction facility, laboratory equipment, and office furniture and fixtures Equipment and machinery at Weldona extraction facility $ 1,120,945 — Golden, Colorado industrial hemp laboratory - equipment 39,944 34,651 Golden, Colorado administrative offices: Furniture and fixtures 49,282 21,668 Leasehold improvements 191,518 2,000 Transportation equipment 191,704 81,667 Remote laboratory equipment 99,220 99,220 Farm Equipment 247,456 — $ 1,940,069 239,206 Accumulated amortization and depreciation (191,897 ) (39,385 ) $ 1,748,172 $ 199,821 The amount of depreciation and amortization expense for the three and six months ended June 30, 2018 is $52,055 and $152,428, respectively. The amount of depreciation and amortization expense for the three and six months ended June 30, 2017 was $3,329 and $12,169, respectively.

PURCHASE OF PRANA THERAPUETICS,

PURCHASE OF PRANA THERAPUETICS, INC.	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Purchase Of Prana Therapuetics Inc.
PURCHASE OF PRANA THERAPUETICS, INC.	NOTE 8 – PURCHASE OF PRANA THERAPUETICS, INC. On June 8, 2017, we entered into an agreement to purchase 400,000 shares of Prana Therapeutics, Inc. (“PTI”), in a private offering of their common shares, for a total consideration of $200,000 (“Subscription Agreement’). In accordance with the terms of the Subscription Agreement, we paid PTI $50,000, upon execution of the Subscription Agreement, and committed to remit $50,000 to PTI on September 30, 2017, December 31, 2017 and March 31, 2018, respectively. Subsequently, on July 14, 2017, we completed the acquisition of PTI in an exchange of 5,730,000 shares of our common stock for 5,730,000 shares of the common stock of PTI. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share of our common stock on the OTC QB Market on July 14, 2017, including the cost to purchase 400,000 shares of PTI for $200,000. The purchase price for PTI was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. The allocation of the purchase price was, as follows: June 30, Patents $ 52,596 Net assets 522,761 Goodwill 4,495,143 Total $ 5,070,500	NOTE 7 – PURCHASE OF PRANA THERAPUETICS, INC. On June 8, 2017, we entered into an agreement to purchase 400,000 shares of Prana Therapeutics, Inc. (“Prana”), in a private offering of their common shares, for a total consideration of $200,000 (“Subscription Agreement’). In accordance with the terms of the Subscription Agreement, we paid Prana $50,000, upon execution of the Subscription Agreement, and committed to remit $50,000 to Prana on September 30, 2017, December 31, 2017 and March 31, 2018, respectively. Subsequently, on July 14, 2017, we completed the acquisition of Prana in a one-for-one exchange of 5,730,000 shares of our common stock for 5,730,000 shares of common stock of Prana. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share of our common stock on the OTC QB exchange on July 14, 2017, including the cost to purchase 400,000 shares of Prana for $200,000. The purchase price for Prana was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. Upon completion of an acquisition audit subsequent to the acquisition of Prana, it was determined that the net assets acquired as of July 14, 2017 were approximately $71,873 more than was reported in the Form 10-Q for the three and nine months ended September 30, 2017. As a result, the allocation of the purchase price, net assets and patent amounts has been restated as of December 31, 2017 compared to September 30, 2017, as follows: December 31, Reallocation September 30, Patents $ 52,596 $ — $ 52,596 Net assets 522,761 71,873 450,888 Goodwill 4,495,143 (71,873 ) 4,567,016 Total $ 5,070,500 $ — $ 5,070,500

GRANTED PATENT

GRANTED PATENT	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Granted Patent
GRANTED PATENT	NOTE 9 – GRANTED PATENTS, NET On August 15, 2017, the United States Patent and Trademark Office issued to the Company US Patent #9730911 (the “Patent”) granting exclusive rights to its proprietary composition of matter in liquid formulations, based on compounds extracted from cannabis plant materials; more specifically the composition of matter pertaining to the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter Patent provides protection for the Company’s proprietary formulations. The Patent protects the use of suspending both phytocannabinoids and cannabinoids with specific combinations of cannabis derived terpenes in liquid forms with an array of delivery methods including capsule, sublingual, topical, oral, suppository, and vaporization. Cannabinoids referenced in the application include ratios of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabichromenic acid (CBCa), and cannabichromene (CBC). At August 15, 2017, we classified the costs associated with research, legal fees, application costs incurred in the process of being granted the Patent on our consolidated balance sheet in the amount of $142,317, and we began amortizing such cost on a straight-line basis over a 15-year period. Amortization expense of the Patent is $3,558 and $0.0 for the six-month period ended June 30, 2018 and 2017, respectively and accumulated amortization is $6,237 and $2,679 at June 30, 2018 and December 31, 2017, respectively.	NOTE 8 – GRANTED PATENT On August 15, 2017, the United States Patent and Trademark Office issued to the Company US Patent #9730911 (the “Patent”) granting exclusive rights to its proprietary formulations based on compounds extracted from cannabis plant materials; more specifically the composition of matter pertaining to the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter Patent provides protection for our proprietary formulations. The Patent protects the use of suspending both phytocannabinoids and cannabinoids with specific combinations of cannabis derived terpenes in liquid forms with an array of delivery methods including capsule, sublingual, topical, oral, suppository, and vaporization. Cannabinoids referenced in the application include ratios of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabichromenic acid (CBCa), and cannabichromene (CBC). At August 15, 2017, we classified the costs associated with research, legal fees, application costs incurred in the process of being granted the Patent on our consolidated balance sheet in the amount of $142,317, and we began amortizing such cost of the Patent on a straight-line basis over a 15-year period. Amortization expense of the Patent is $2,679 and $0.00 for the year ended December 31, 2017 and 2016, respectively, and accumulated amortization is $2,679 and $0.00 at December 31, 2017 and 2016, respectively.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 10 – INTANGIBLE ASSETS Our intangible assets are comprised of the costs incurred in pursuing provisional patent applications and applications for design mark and trademarks, which have presently not been approved or issued. The costs associated with our intangible assets are amortized on a straight-line basis over estimated useful lives of 15 years for patents and 10 years for design marks and trademarks once the applications are approved. Costs associated with applications that are not approved will be expensed in the period that the application is rejected or abandoned.	NOTE 9 – INTANGIBLE ASSETS Our intangible assets are comprised of the costs incurred in pursuing provisional patent applications and applications for design mark and trademarks, which have presently not been approved or issued. The costs associated with our intangible assets are amortized on a straight-line basis over estimated useful lives of 15 years for patents and 10 years for design marks and trademarks, once the applications are approved. Costs associated with applications that are not approved will be expensed in the period that the application is rejected or abandoned.

EQUITY METHOD INVESTMENTS

EQUITY METHOD INVESTMENTS	12 Months Ended
	Dec. 31, 2017
Equity Method Investments and Joint Ventures [Abstract]
EQUITY METHOD INVESTMENTS	NOTE 10 – EQUITY METHOD INVESTMENTS On August 15, 2014, we acquired a 50% interest in Cannabinoid Research & Development Company Limited (“CRD”), a Jamaican company, in exchange 40,000 shares of our common stock valued at $88,000 based on the previous day’s closing price of our stock. We also committed to provide expertise on design-build, genetics, cultivation, production, processing, productizing, labeling, packaging, marketing, branding and distribution of products, as well as use of our intellectual property in the operations of CRD. We accounted for this $88,000 as an equity method investment on our condensed consolidated balance sheets at December 31, 2016. At March 31, 2017, it was concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
ACCRUED EXPENSES	NOTE 11 – ACCRUED EXPENSES Our accrued expenses consist of: December 31, 2017 2016 Accrued consulting fees $ — $ 45,000 Accrued wages and related expenses 10,184 — Accrued interest expense — 10,264 Total accrued expenses $ 10,184 $ 55,264 On May 6, 2014, we entered into a consultancy agreement with two third party consultants that had a nine-month term, which could be renewed and/or extended by mutual agreement. The agreement provided for a $50,000 payment at signing, which has been paid, and for three more $50,000 payments (a total of $200,000) and the issuance of 100,000 shares of our common stock upon the achievement of certain goals, as set forth in appendix II of the agreement. During the year ended December 31, 2014 we recognized $160,000 of expense applicable to this agreement. At December 31, 2015, the project was approximately 80% complete and $110,000 is included in accrued expenses on our consolidated balance sheet at that date. On December 7, 2016, upon mutual agreement, the consultancy agreement was deemed to be abandoned, because the project was not completed. In turn, one of the consultants, Dr. Brent Reynolds, has been performing other services for the Company during the year ended December 31, 2016, and has agreed to join our Board of Advisors. Dr Reynolds is currently a professor in the Department of Neurosurgery at the University of Florida, College of Medicine, where his lab focuses on the application of natural products for treating diseases and dysfunction of the nervous system. In recognition of his services to the Company during the year ended December 31, 2016, and as an inducement to join our Board of Advisors, he was issued 100,000 shares of our common stock for such services, and the fair market value of these shares in the amount of $163,783 was charged to common stock on the consolidated balance sheet at December 31, 2016, and the residual amount of $53,783 was recognized as a loss on the extinguishment of a debt in our consolidated statement of operations.

INSTALMENT LOAN PAYABLE

INSTALMENT LOAN PAYABLE	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Instalment Loan Payable
INSTALMENT LOAN PAYABLE	NOTE 11 – INSTALLMENT LOANS PAYABLE Installment loans payable consists of a 48-month installment loan for the purchase of a truck that is used at our extraction facility, as well as a 36-month installment loan for the purchase an SUV used for Company purposes. The outstanding balance on the 48-month installment loan was $17,892 and $46,667 at June 30, 2018, and December 31, 2017, respectively. The terms of the 48-month installment loan specify monthly payments of $955, however, we are making payments of $6,955 per month to pay the loan off in a six-month period. As a result of our intentions to pay the loan off in six months, the entire balance of the 48-month installment loan has been classified as a current liability. The outstanding balance on the 36-month installment loan was $76,715 and $0 at June 30, 2018, and December 31, 2017, respectively. The terms of the 36-month installment loan specify monthly payments of $2,160, however, we are making payments of $6,500 per month to pay the loan off within a one-year period. As a result of our intentions to pay off the loan within one year, the entire balance of the 36-month installment loan has been classified as a current liability.	NOTE 12 – INSTALMENT LOAN PAYABLE Instalment loan payable consists of a 48-month instalment loan incurred in connection with the purchase of a truck that is used at our extraction facility. The outstanding balance on the instalment loan is $46,667 and $0.0 at December 31, 2017 and 2016, respectively. The terms of the installment loan specify monthly payments of $972, however, we are making payments of $7,778 per month in order to pay the loan off in a six-month period. As a result of our intentions to pay the loan off in six months, the entire balance of the instalment loan has been classified as a current liability.

DEFERRED REVENUE

DEFERRED REVENUE	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE.	NOTE 12 – DEFERRED REVENUE Our deferred revenue consists of: June 30, December 31, 2018 2017 Current portion $ 113,750 $ 180,000 Long term portion — 23,750 Deferred revenue $ 113,750 $ 203,750 On June 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WeedMD (“WMD) in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and we recognized $150,000 of this amount as revenue during the period July 1, 2014 through December 31, 2014, based upon our initial three-year estimate of the service period involved. Based on recent discussions with WMD, we now expect to deliver the remaining consulting services and use of our intellectual property to WMD on a relatively consistent monthly basis during the four-year period from January 1, 2015 through December 31, 2018. Accordingly, we are now recognizing $15,000 of deferred revenue per month. We recognized $90,000 of revenue applicable to this arrangement in each of the six months ended June 30, 2018 and 2017, respectively. At June 30, 2018, we expect to recognize the remaining $135,750 WMD deferred revenue during the next twelve months, and accordingly, we have classified the $113,750 as a current liability on our consolidated balance sheets.	NOTE 13 – DEFERRED REVENUE Our deferred revenue consists of: December 31, 2017 2016 Deferred revenue – WeedMD $ 203,750 $ 383,750 Less – current portion (180,000 ) (180,000 ) Deferred revenue, net of current portion $ 23,750 $ 203,750 On June 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and we recognized $150,000 of this amount as revenue during the period July 1, 2014 through December 31, 2014, based upon our initial three-year estimate of the service period involved. Based on recent discussions with WMD, we now expect to deliver the remaining consulting services and use of our intellectual property to WMD on a relatively consistent monthly basis during the four-year period January 1, 2015 through December 31, 2018. Accordingly, we are now recognizing $15,000 of deferred revenue per month. We recognized $180,000 of revenue applicable to this arrangement, in each of the years ended December 31, 2017 and 2016. At December 31, 2017, we expect to recognize $180,000 of the remaining $203,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $180,000 as a current liability on our consolidated balance sheets. On December 28, 2014, we entered into a royalty and consulting services agreement with FoxBarry Farms, LLC (“FoxBarry”) whereby we received a $200,000 prepaid royalty payment from FoxBarry. At the time, we planned to recognize deferred royalty revenue based on actual applicable sales as defined in the agreement. In August 2015, we discontinued providing consulting services to FoxBarry, as our initial project with FoxBarry was abandoned due to operational issues. However, FoxBarry appears to no longer be in existence, and since all of our conditions pursuant to the agreement have been satisfied, we elected to recognize the $200,000 of deferred income during the year ended December 31, 2016, as other income.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
CONVERTIBLE NOTE PAYABLE [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 13 – CONVERTIBLE NOTES PAYABLE During the six months ended June 30, 2018, we issued convertible promissory notes to an unaffiliated third party. The net proceeds from these notes were used for general working capital purposes. The debt discounts and deferred financing costs on the convertible promissory notes are amortized on a straight-line basis, which approximates the effective interest rate method, over the term of the note, and this amortization is included in interest expense in our consolidated statements of operations. The following table summarizes our convertible promissory notes outstanding as of June 30, 2018 and December 31, 2017: Issue Holder Security Maturity Interest Base June 30, December 31, 4-02-18 Tangiers Global Unsecured 10-04-18 5% Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holders election to convert $ 600,000 $ — 6-04-18 Tangiers Global Unsecured 12-04-18 5% Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holders election to convert 288,750 — Less unamortized Discount (26,931 ) — $ 861,819 $ — During the three months and six months ended June 30, 2018, we recognized $16,819 of amortization of deferred financing costs, respectively. This amount is included in interest expense in our consolidated statements of operations.	NOTE 14 – CONVERTIBLE NOTES PAYABLE During the year ended December 31, 2016, we issued convertible promissory notes to unaffiliated third parties, the proceeds of which used for general working capital purposes. The debt discounts and deferred financing costs on the convertible promissory notes are amortized on a straight-line basis, which approximates the effective interest rate method, over the term of the note, and this amortization is included in interest expense in our consolidated statements of operations. The following table summarizes our convertible promissory notes outstanding as of December 31, 2017 and 2016: Maturity Interest Base December 31, Issue Date Holder Security Date Rate Conversion Rate 2017 2016 12/28/2016 Tangiers Investment Group Unsecured 7/8/2017 10 % $1.00 through maturity; 55% of lowest closing price thereafter $ — $ 35,000 8/10/2016 JSJ Investments Unsecured 5/10/2017 12 % $0.20 during first 180 days; 45% of lowest closing price thereafter — 125,000 — 160,000 Less unamortized discount — (34,453 ) $ — $ 125,547 The convertible notes, including accrued interest payable, may be converted into shares of our common stock at the Conversion Price, in whole, or in part, at various times, after the date of issuance, at the option of the holder (the “Conversion Feature”), as defined by the terms of the convertible note. The Conversion Price is equal to the Base Conversion Rate specified in the table above multiplied by the Variable Conversion Rate (“VCR”) which is equal to the average of the number of lowest trading prices or closing bid prices of our common stock (specified in the table above) during the ten-trading day period prior to the date of conversion divided by the closing price of our common stock on the day of conversion. If these conversion rates result in a beneficial conversion feature (“BCF”), the BCF is recorded as an unamortized convertible debt discount, which is required to be valued and amortized to interest expense over the term of the Note. We amortize our convertible debt discount on a straight-line basis, which approximates the effective interest rate method, and this amortization is included in amortization of debt discount in our consolidated statements of operations. If a convertible note is repaid, any remaining unamortized deferred financing costs and unamortized debt discount are expensed on the date of repayment. If a convertible note is convertible into an unlimited number of unregistered, restricted common shares, it is classified as having an unlimited shares feature (“Unlimited Shares Feature”). The difference between the closing price of our common stock and the VCR is referred to as the Variable Conversion Rate Differential (“VCRD”). If, both the Unlimited Shares Feature and the VCRD meet the definition of an embedded derivative, then together they create a compound embedded derivative liability or, hereafter, simply a “derivative liability.” In accordance with U.S. GAAP, our derivative liabilities are recorded at fair value on the date of issuance and subsequently remeasured to fair value each reporting period with any change in fair value being recognized as gain (loss) on derivative liabilities in our consolidated statement of operations. See Note 9. Similarly, accrued interest payable applicable to the convertible notes is convertible into shares of our common stock, without limit, at the same Conversion Price. The fair value of the derivative liabilities applicable to accrued interest payable is measured and recognized at each reporting date as derivative liabilities with a corresponding charge to interest expense. As noted above, all derivative liabilities are re-measured in subsequent reporting periods with any change in fair value being included in gain (loss) on derivative liabilities. During the years ended December 31, 2017 and 2016 we recognized $0.00 and $34,415 of amortization of deferred financing costs, respectively. This amount is included in interest expense in our consolidated statements of operations. We recognized $30,543 and $35,719 of interest expense applicable to our convertible notes during the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017, and 2016, $0.00 and $5,876, respectively, of this interest is accrued within accrued expenses on our consolidated balance sheets. 2015 Convertible Notes At various times during the year ended December 31, 2015, the Company issued convertible promissory notes (the "2015 Notes") in the aggregate principal balance of $381,000. The 2015 Notes, including accrued interest payable, may be converted into shares of our common stock at the Conversion Price, as defined below, in whole, or in part, at any time beginning 180 days after the date of issuance, at the option of the holder. The 2015 Notes also contain prepayment options whereby we may, during the first 180 days that each note is outstanding, prepay the note by paying prepayment premiums ranging from 10% to 40% of the principal then outstanding depending on the date of prepayment. In general, per the terms of our 2015 Notes, the note holders may not make any conversions that would result in the note holder holding more than 9.99% of our issued and outstanding common stock at any one time. Should we default on a conversion or repayment of a convertible note, the note, accrued interest and default penalties and fees are immediately due and payable. The minimum default penalty amount ranges from 25% to 50% (or more, under certain circumstances) times the then outstanding principal and unpaid interest. During the year ended December 31, 2016, two of these notes in the aggregate principal balance of $161,000 were repaid. The $220,000 note dated December 9, 2015 from Tangiers Investment Group, LLC was converted in full into a total of 2,843,698 shares of the Company's common stock at various dates during the year ended December 31, 2016. Slainte Convertible Notes On March 30, 2016, we borrowed $81,978, from Slainte Ventures and used the proceeds to repay principal and accrued interest applicable to our $59,000 convertible promissory note dated October 6, 2015, to Vis Vires Group, Inc. On April 6, 2016, we borrowed an additional $75,000 from Slainte Ventures and used the proceeds, along with $52,500 of advances to the Company by officers and directors of the Company, to repay principal and accrued interest applicable to our $102,000 convertible promissory note, dated October 12, 2015, to JSJ Investments, Inc. On July 5, 2016, we borrowed $50,000 from Slainte Ventures and used the proceeds for working capital purposes. These loans, together with interest at 12% per year, are payable on December 30, 2016. We can prepay the loans at any time. If the loans are repaid on or before September 30, 2016, the principal amount which is being repaid will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount which is being repaid will increase by 15%. The amount of the principal increase may be paid with shares of our common stock. The number of shares to be issued for such purpose will be determined by dividing the average closing price of our common stock (which in no case can be greater than $0.45) for the ten trading days preceding the prepayment date. The original principal of the loan was not convertible prior to maturity. If the loans were not paid when due, then at any time between the maturity date and January 10, 2017, Slainte may convert the outstanding principal and interest on the loan into shares of our common stock. The number of shares to be issued on conversion was to be determined by dividing the average closing price of our common stock (which in no case can be greater than $0.45) for the ten trading days preceding the conversion date by the outstanding principal and interest on the loan on the conversion date. The notes were not paid prior to the maturity date of December 30, 2016. As a result, the notes became convertible effective December 31, 2016. Derivative liabilities in the aggregate amount of $557,000 were recorded upon these notes becoming convertible. The notes along with their accrued interest were converted into 497,296 shares of the Company's common stock on December 31, 2016, and the value of the derivative liabilities were extinguished to common stock. JSJ Convertible Note On August 10, 2016, we borrowed $125,000 from JSJ Investments and used the proceeds for working capital purposes. The loan, together with interest at 12% per year, is payable on May 10, 2017. We can prepay the loan at any time. If the loan is repaid on or before October 16, the principal amount which is being repaid will increase by 25%. If the loan is repaid on or before October 16, 2016 through February 12, 2016, the principal amount which is being repaid will increase by 30%. Thereafter, the note may be repaid only upon written consent from JSJ, and the principal amount that is being repaid will increase by 30%. At any time after the date of the note, JSJ is entitled to convert all of the outstanding and unpaid principal in to shares of our common stock. Until February 12, 2017, the conversion price is $0.20 per share, and thereafter, the conversion price will be at a 45% discount to the lowest closing price of our common stock for the ten trading days preceding the conversion date. JSJ may not make any conversions that would result in the note holder holding more than 4.99% of our issued and outstanding common stock at any one time. If the notes are held through February 12, 2017, derivative accounting will apply upon the change to a variable conversion price. This convertible note was paid in full on February 9, 2017. Tangiers Convertible Note In connection with our equity line agreement, the Company issued a promissory note to Tangiers for the principal sum of $35,000 as a commitment fee for the equity line. The note bears interest at 10% per year, is unsecured, and is due and payable on July 8, 2017. At the option of Tangiers, all or any part of the unpaid principal amount of the note may be converted into shares of the Company's common stock. The number of shares to be issued on any conversion will be determined by dividing the principal amount of the note to be converted by $1.00. If the note is not repaid or converted prior to maturity, the conversion price will change to 55% of the lowest closing bid price during the 20 days preceding the conversion date. If the note is held past maturity, derivative accounting will apply upon the change to a variable conversion price. This note was paid off on May 19, 2017.

NOTES PAYABLE TO AND ADVANCES F

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
NOTES PAYABLE, RELATED PARTIES [Abstract]
NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS	NOTE 14 – NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS Notes payable to and advance from officers and directors consisted of the following: June 30, December 31, 2018 2017 Note payable to Earnie Blackmon, an officer and director $ 745,945 $ 246,458 Note payable to Tony Verzura, an officer and director 16,644 14,889 $ 762,589 $ 261,347 On April 6, 2016, we borrowed $25,000 from Ernest Blackmon and $25,000 from Tony Verzura and used the proceeds to repay principal and interest applicable on our $102,000 convertible promissory note dated October 12, 2015, to JSJ Investments Inc. The loans, together with interest at 12% per year, are payable on December 30, 2016. We may prepay the loans at any time. If the loans are repaid on or before September 30, 2016, the principal amount, which is being repaid, will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount, which is being repaid will increase by 15%. As of December 31, 2016, the loans were not repaid, when they were due, per the terms of the notes, and thus, the principal balance of the notes was increased to $57,500 in the aggregate, with the addition to the principal balance charged to interest expense. Historically, Messrs. Blackmon, Verzura and Ruby, who are officers and directors of the Company, have paid obligations and expenses on behalf of the Company, from their own individual, personal funds. Such payments have been recorded in the consolidated balance sheets as a component of Notes payable to and advances from officers and directors. During the six months ended June 30, 2018, Mr. Blackmon, the Chairman, Chief Executive Officer and President of the Company paid $473,516 of obligations and expenses of the Company from his own personal funds. These payments have been recorded in the consolidated balance sheets as a component of Notes payable to and advances from officers and directors.	NOTE 15 – NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS Notes payable to and advance from officers and directors consisted of the following, at December 31, 2017 and 2016: December 31, 2017 2016 Note payable to Earnie Blackmon, an officer and director $ 246,458 $ 28,750 Note payable to Tony Verzura, an officer and director 14,889 28,750 $ 261,347 $ 57,500 On April 6, 2016, we borrowed $25,000 from Ernest Blackmon and $25,000 from Tony Verzura and used the proceeds to repay principal and interest applicable on our $102,000 convertible promissory note dated October 12, 2015, to JSJ Investments Inc. The loans, together with interest at 12% per year, are payable on December 30, 2016. We may prepay the loans at any time. If the loans are repaid on or before September 30, 2016, the principal amount, which is being repaid, will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount, which is being repaid will increase by 15%. As of December 31, 2016, the loans were not repaid, when they were due, per the terms of the notes, and thus, the principal balance of the notes was increased to $57,500 in the aggregate, with the addition to the principal balance charged to interest expense. During the years ended December 31, 2017 and 2016, Messrs. Blackmon, Verzura and Ruby, who are officers and directors of the Company, paid obligations and expenses on behalf of the Company, from their own individual, personal funds. Such payments have been recorded in the consolidated balance sheets as a component of Notes payable to and advances from officers and directors.

ARBITRATION SETTLEMENT RESERVE

ARBITRATION SETTLEMENT RESERVE	6 Months Ended
	Jun. 30, 2018
Loss Contingency [Abstract]
ARBITRATION SETTLEMENT RESERVE	NOTE 15 – ARBITRATION SETTLEMENT RESERVE On May 8, 2018, H2, LLC (“H2”) and the Company executed a letter of intent formalizing the intent to enter into a joint venture. The parties subsequently made advances in anticipation of formalizing the joint venture through a definitive agreement. However, the joint venture was never formalized, and the letter of intent was terminated pursuant to its terms. Under the terms of the provisions in the letter of intent that survived its termination, the Company has the option to either provide H2 with 25% of the industrial hemp seeds purchased with $650,000 advanced by H2, or to refund the $650,000 advanced by H2. Pursuant to another provision in the letter of intent that survived termination, disputes are to be resolved via arbitration in Denver, Colorado. The parties are currently negotiating to resolve the dispute. Although the actual result of negotiations or of arbitration are not presently determinable with certainty, we have established an arbitration settlement reserve in the amount of $650,000, which we believe is the maximum amount that H2 might be awarded in arbitration.

STOCKHOLDERS' EQUITY (DEFICIT)

STOCKHOLDERS' EQUITY (DEFICIT)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 16 – STOCKHOLDERS’ EQUITY Preferred Stock On July 18, 2017, the Board of Directors adopted a resolution creating a series of Preferred Shares, designated as the Series A Preferred Shares. We subsequently issued 2,000 shares of our Series A preferred stock for $2,200 to certain of our officers and to each director. Warrants: The following table summarizes our warrants outstanding as of June 30, 2018 and December 31, 2017: June 30, December 31, 2018 2017 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,209,025 $ 0.21 $ 1,551,356 $ 0.18 Warrants issued to consultants 50,004 132,669 Warrants exercised — (475,000 ) Warrants outstanding, end of period 1,259,029 $ 0.29 1,209,025 $ 0.21 Warrants exercisable, end of period 1,259,029 $ 0.29 1,209,025 $ 0.21 The weighted-average remaining contractual life for warrants outstanding and exercisable at June 30, 2018, is 3.6 years, and the aggregate intrinsic value of warrants outstanding and exercisable at June 30, 2018 is $0. 666,667 warrants issued during the year ended December 31, 2017 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % 50,004 warrants issued during the six months ended June 30, 2018 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % Stock Options On February 28, 2018, we awarded 6,000,000 stock options to various employees under our 2017 Stock Incentive Plan. Of these options, 5,125,000 were fully vested at the time of grant with the remaining 875,000 vesting quarterly through December 31, 2019. The awarded options give the option holder the right to purchase shares of our common stock at $1.08 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.91 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 1.05 Exercise price $ 1.08 Risk free interest rate 2.8 % Expected term (years) 5-10 Expected volatility 197 % Expected dividends 0 % The total grant-date fair value of these options was approximately $6,146,000. Stock-based compensation expense related to these stock options included in operating expenses for the six months ended June 30, 2018 was approximately $5,324,754. On June 29, 2018, we awarded 14,195,000 stock options to various employees under our 2018 Stock Incentive Plan. Of these options, 13,250,000 were fully vested at the time of grant with the remaining 945,000 vesting quarterly through July 1, 2022. The awarded options give the option holder the right to purchase shares of our common stock at $0.705 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.59 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.71 Exercise price $ 0.95 Risk free interest rate 2.68 - 2.79 % Expected term (years) 5 Expected volatility 210% - 214 % Expected dividends 0 % The total grant-date fair value of these options was approximately $9,711,400. Stock-based compensation expense related to these stock options included in operating expenses for the three months ended June 30, 2018 was approximately $9,053,341. The following table summarizes our stock options outstanding as of both June 30, 2018 and December 31, 2017, respectively: Number of Weighted Weighted Stock options outstanding at January 1, 2017 3,680,000 8.9 $ 0.28 Issued 3,957,500 9.9 0.64 Exercised (1,000,000 ) Expired — Stock options outstanding at December 31, 2017 6,637,500 8.7 $ 0.57 Stock options exercisable at December 31. 2017 6,637,500 8.7 0.57 Stock options outstanding at December 31, 2017 6,637,500 Issued 20,195,000 9.8 0.83 Exercised — Expired — Stock options outstanding at June 30, 2018 26,832,000 9.9 0.75 Stock options exercisable at June 30, 2018 25,080,000 9.5 $ 0.74 The total price to exercise all outstanding stock options is $14,301,000. The weighted-average remaining contractual life for stock options outstanding and exercisable at June 30, 2018 is 9.9 years, and the aggregate intrinsic value of options outstanding and exercisable at June 30, 2018 is $0.75. On July 25, 2018, we repriced the exercise price per share from $1.08 to $0.58 per share for the stock options to purchase 6,000,000 shares of our common stock that were granted on March 28, 2018 and repriced the exercise price per share from $0.705 to $0.58 per share for the stock options to purchase 14,195,000 of our common stock that were granted on June 29, 2018. No adjustment to shared-based compensation in the consolidated financial statements for the three and six months ended June 30, 2018 was necessary as a result of the repricing of the stock options.	NOTE 16 – STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock On July 18, 2017, the Board of Directors adopted a resolution creating a series of Preferred Shares, no par value per share, designated as the Series A Preferred Shares. We subsequently issued 2,000 shares of our Series A preferred stock for $2,200 to of our officers and directors. Warrants: The following table summarizes our share warrants outstanding as of December 31, 2017 and 2016: Year Ended December 31, 2017 2016 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,551,356 $ 0.18 $ 3,000,000 $ 12.00 Warrants issued to consultants 132,669 — 666,667 0.18 Cashless warrants issued upon conversion of Slainte note — — 1,584,689 — Warrants exercised (475,000 ) — (700,000 ) — Expired — — (3,000,000 ) — Warrants outstanding, end of period 1,209,025 $ 0.21 1,551,356 $ 0.18 Warrants exercisable, end of period 1,209,025 $ 0.21 1,551,356 $ 0.18 The weighted-average remaining contractual life for warrants outstanding and exercisable at December 31, 2017, is 3.0 years, and the aggregate intrinsic value of warrants outstanding and exercisable at December 31, 2017 is $0. 666,667 and 83,333 warrants issued during the years ended December 31, 2017 and 2016, respectively, were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % Stock Options On January 9, 2015, we awarded 200,000 stock options to each of Messrs. Blackmon, Verzura and Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and give the option holder the right to purchase shares of our common stock at $0.70 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.70 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.70 Exercise price $ 0.70 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % At December 31, 2014, the fair value of these 600,000 options totaling $417,664 was included in accrued expenses on our consolidated balance sheets. On January 9, 2015, the option grant date, we increased common stock and decreased accrued expenses by this amount to account for the issuance of the 600,000 options on that date. On January 12, 2016, we awarded 1,050,000 stock options to each of Messrs. Blackmon, Verzura and 980,000 stock options to Mr. Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and give the option holder the right to purchase shares of our common stock at $0.20 per share during the ten year term of the option. We calculated the fair value of each option to be approximately $0.20 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.20 Exercise price $ 0.20 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % At December 31, 2015 the fair value of these 3,080,000 options totaling $612,512, which was included in accrued expenses on our consolidated balance sheets, and on January 15, 2016, the option grant date, we increased common stock and decreased accrued expenses by this amount to account for the issuance of these options on that date. The following table summarizes our stock options outstanding as of both December 31, 2017 and 2016, respectively: Number of Weighted Weighted Stock options outstanding at December 31, 2015 600,000 9.8 $ 0.70 Issued 3,080,000 10.0 $ 0.20 Exercised — — — Expired — — — Stock options outstanding at December 31, 2016 3,680,000 8.9 $ 0.28 Issued 3,957,500 Exercised (1,000,000 ) Expired — Stock options exercisable at December 31, 2017 6,637,500 8.7 $ 0.57 The weighted-average remaining contractual life for stock options outstanding and exercisable at December 31, 2017, is 8.7 years, and the aggregate intrinsic value of options outstanding and exercisable at December 31, 2017 is $0.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 17 – SHARE-BASED COMPENSATION We recognize share-based compensation expense in cost of revenues, sales and marketing expenses, research and development expenses, general and administrative expenses, and other income and expenses, based on the fair value of common shares issued for services. In addition, we accrue share-based compensation expense for estimated share-based awards earned during the six months ended June 30, 2018 and 2017, Stock Incentive Plans. Share-based compensation expense for the six months ended June 30, 2018 and 2017 is, as follows: Three Months Ended Six Months Ended 2018 2017 2018 2017 Options granted to officers, directors and employees $ 9,185,725 $ 1,624,000 $ 14,510,479 $ 1,568,000 Common stock issued for accounts payable and accrued expenses — — — 43,676 Options granted for services 26,318 — 51,320 — Warrants and options issued for consulting services — 125,826 — 217,159 Common stock issued for services 110,506 75,918 225,393 196,534 Common stock issued as compensation to employees 145,000 — 178,500 — $ 9,467,549 $ 1,825,744 $ 14,965,692 $ 2,025,369 The stock options issued to officers and directors were issued under the 2018 Stock Incentive Plan, and such shares were fully vested at the date of grant.	NOTE 17 – SHARE-BASED COMPENSATION Share-based Compensation We recognize share-based compensation expense in cost of revenues, sales and marketing expenses, R&D expenses, general and administrative expenses, and other income and expenses, based on the fair value of common shares issued for services. In addition, we accrue share-based compensation expense for estimated share-based awards earned during the years ended December 31, 2017 and 2016, under our 2014 Equity Incentive Plan and our 2017 Equity Incentive Plan. Share-based compensation expense for the years ended December 31, 2017 and 2016 is, as follows: December 31, 2017 2016 Warrants issued for consulting and other services $ 249,835 $ 319,419 Common stock issued for accounts payable and accrued expenses 93,002 223,484 Common stock issued for services — 271,097 Common stock issued upon conversion of debt and loss on extinguishment of debt 381,576 — Common stock issued for advisory board fees 113,336 — Common stock issued as compensation to employees 170,233 — Common shares issued in settlement of dispute 102,139 — Stock options issued to officers and directors 2,660,159 — $ 3,770,279 $ 814,000

SIGNIFICANT CUSTOMER INFORMATIO

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY	6 Months Ended
	Jun. 30, 2018
Risks and Uncertainties [Abstract]
SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY	NOTE 18 – SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Six Months Ended June 30, 2018 2017 Customer A 27% 50% Customer B 24% 49% Customer C 14% 1% Percentage of Accounts Receivable: As of June 30, 2018 2017 Customer C 100% —% Customer D —% —% Customer E —% —% The following tables show significant concentrations in our expenses and accounts payable for the periods indicated: Percentage of Expenses: Six Months Ended June 30, 2018 2017 Vendor A 17% —% Vendor B 14% —% Vendor C 11% —% Percentage of Accounts Payable: As of June 30, 2018 2017 Vendor C 26% —% Vendor D 17% —% Vendor E 8% —%

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 18 – INCOME TAXES The Internal Revenue Code (“IRC”) allows net operating losses (“NOL's”) to be carried forward and applied against future profits for a period of twenty years. The change of ownership following our merger with MySkin may limit our ability to utilize these NOLs under the terms of IRC Section 381. We did not provide any current or deferred federal income tax provision or benefit for any of the periods presented in our consolidated financial statements because we have experienced losses since our inception. When it is more likely than not, that a tax asset cannot be realized through future income, we must record an allowance against any potential future tax benefit. We provided a full valuation allowance against our net deferred tax assets, consisting of net operating loss carry forwards, because we determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carry forward periods. We have not taken a tax position that, if challenged, would have a material effect on our consolidated financial statements for the years ended December 31, 2017 and 2016, as defined under ASC 740. We did not recognize any adjustment to our liability for uncertain tax positions and therefore did not record any adjustment to the beginning balance of our accumulated deficit on our consolidated balance sheets. Our provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences for the periods presented are as follows: Years Ended December 31, 2017 2016 Statutory U.S. federal tax rate 39 % 39 % Effect of increase in valuation allowance (39 %) (39 %) — % — % Changes in our cumulative net deferred tax assets consist of the following: December 31, 2017 2016 Net loss carry-forward $ 4,923,492 $ 3,648,316 Valuation allowance (4,923,492 ) (3,648,316 ) $ — $ — A reconciliation of our income taxes computed at the statutory rate is as follows: Years Ended December 31, 2017 2016 Tax benefit at statutory rate $ 2,023,555 $ 1,500,068 Valuation allowance (2,023,555 ) (1,500,068 ) $ — $ —

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 19 – COMMITMENTS AND CONTINGENCIES Contractual Obligations and Commercial Commitments Financing Commitment On January 19, 2018, we entered into an equity line of credit agreement with Tangiers Global, LLC (“Tangiers”). Under the equity line agreement, Tangiers has agreed to provide the Company with up to $10,000,000 of funding through the purchase of shares of the Company’s common stock. During the term of the agreement, the Company may deliver a put notice to Tangiers, which will specify the number of shares which the Company will sell to Tangiers. The maximum amount that the Company shall be entitled to put to Tangiers per any applicable put notice is that number of shares of our common stock up to or equal to 400% of the average of the daily trading volume of our common stock for the eight consecutive trading days immediately prior to the date of the applicable put notice. The minimum amount the Company can draw down at any one time is $5,000, and the maximum amount the Company can draw down at any one time is $1,000,000, as determined by multiplying the put amount by the average daily volume weighted average prices of our common stock for the ten (10) trading days immediately prior to the applicable put notice. A closing will occur on the date which is no earlier than five (5) trading days following, and no later than seven (7) trading days following, the applicable put notice. On each closing date, the Company will sell, and Tangiers will purchase, the shares of the Company’s common stock specified in the put notice. The amount to be paid by Tangiers on a particular closing date will be determined by multiplying the purchase price by the number of shares specified in the put notice. The purchase price is 85% of the average the two lowest volume weighted average trading prices of the Company’s common stock during the pricing period applicable to the put notice. The pricing period, with respect to a particular put notice, is five consecutive trading days including, and immediately following, the delivery of a put notice to Tangiers. The Company may submit a put notice once every eight trading days, provided the closing of the previous transaction has taken place. The Company is under no obligation to submit any put notices. The Company subsequently delivered four (4) put notices to Tangiers, and, as of June 30, 2016, received $2,581,108, under the terms of the equity line of credit agreement from the sale of 2,907,944 shares of the Company’s common stock to Tangiers. Clinical Trial Agreement Under the terms of an agreement dated November 11, 2017, we committed to pay the costs to perform clinical trials with The University of the West Indies through the Topical Metabolism Research Unit of the Caribbean Institute for Health Research located in Kingston, Jamaica, initially scheduled as follows: · An instalment of $50,000 upon both the approval of specific protocol by the Ethics Committee of the Institutional Review Board of the Ministry of Health, Jamaica, and the execution of the clinical trial agreement, · An instalment of $51,182 upon the enrollment of the 12 th · An instalment of $51,182 after all twelve patients go through the washout period determined in the specific protocol and return for a second dose, and · An instalment of $51,182 upon completion of the clinical trial. Additionally, we have agreed to reimburse The University of the West Indies for care and treatment of patients suffering adverse reactions or injury sustained by a patient, as a direct result of the clinical trial. Research Laboratory In October 2017, our 95% owned subsidiary, Prana Therapeutics, Inc (“PTI”), entered into a research agreement with the University of Florida Trustees (“UFT”). Under the terms of the research agreement PTI committed to pay UFT $303,544 in four (4) installments, of which $75,886 is owing as of June 30, 2018. Executive Office Lease Effective August 1, 2017, we signed a thirty-six-month lease of approximately 6,683 square feet of commercial office space in Golden, Colorado that we use as our executive offices. The lease expires on July 31, 2020 and requires the payment of monthly base rental rates of $3,302 through July 31, 2018, $3,000 through July 31, 2019 and $3,799 through July 31, 2020. As additional rent, we are required to pay for an allocation of common area costs and expenses, plus all utilities. Future minimum payments for this lease are: For the Twelve Months Ending June 30, 2019 2020 2021 2021 2022 $41,802 $45,295 $3,800 $0 $0 Extraction Facility Lease Effective October 1, 2017, we entered into a lease of approximately 40,000 square feet of industrial space in Weldona, Colorado that we us as our industrial hemp extraction facility and industrial hemp cultivation center. The term of the lease expires on October 31, 2018, with an annual option to renew that expires on September 30, 2022. The rent is $7,500 per month throughout the term of the lease, plus we are responsible for all utilities. Industrial Hemp Crop Under Cultivation We entered into a farm lease for acreage on which the Company is growing an industrial hemp crop. The rent for the acreage under the terms of the farm lease is in an amount per acre predicated upon the total weight in pounds of industrial hemp flower harvested at a rate of $2 per pound (dry weight, after thrashing to remove seeds), with a minimum of $1,000 per acre. The rent is payable in three (3) installments; (i) one third on November 15, 2018, (ii) one third on December 31, 2018 and (iii) the remainder of all rents is payable on February 15, 2019. Industrial Hemp Crop Under Cultivation – Transaction With and Commitment to a Related Party Approximately 30% of the farm acreage, on which we are growing our industrial hemp crop, is contractually controlled by a joint venture, NEC Agri Services, LLC (“NEC”). Our Principal Financial Officer is one of the managing members and owners of NEC. In exchange for supplying the farm acreage along with certain farm equipment, infrastructure and our lead farmer and farm management, the Company agreed to pay NEC a stipulated dollar amount per weight in pounds of industrial hemp flower harvested on the NEC farm acreage (dry weight after thrashing for the removal of seeds), reduced by a ratable allocation per acre of total farming costs for the industrial hemp crop under cultivation. We believe the stipulated dollar amount per weight in pounds is commensurate to the fair market value that we could have received from an independent farmer and land owner.	NOTE 19 – COMMITMENTS AND CONTINGENCIES Contractual Obligations and Commercial Commitments Consulting Agreement for GAAP Reporting Services On February 20, 2016, we entered into a consulting agreement with a third party that has a twelve-month term, and which can be extended by mutual agreement. The agreement provides for the issuance of a five (5) year warrant to the consultant, upon the execution of the agreement, to purchase 250,000 shares of our common stock at a price of $0.18 per share, plus the payment of $7,500 on the first day of each month, beginning March 1, 2016, coupled with the monthly issuance of five (5) year warrants to purchase our common stock in a number of shares determined by dividing $7,500 by $0.18 per share. These warrants are exercisable at a price of $0.18 per share. During the years ended December 31, 2017 and 2016, we recognized in our consolidated statements of operations expenses in the total amount of $156,630 and $394,215, respectively, related to this contract, as follows: December 31, 2017 2016 Cash paid to consultant $ 30,000 $ 15,000 Fair value of shares of common stock issued to consultant 27,297 62,781 Fair value of warrants issued to consultant 99,333 319,419 $ 156,630 $ 397,200 Financing Commitment On December 28, 2016, we entered into an equity line of credit agreement with Tangiers Global, LLC (“Tangiers”). Under the equity line agreement, Tangiers has agreed to provide the Company with up to $10,000,000 of funding through the purchase of shares of the Company’s common stock. During the term of the agreement, the Company may deliver a put notice to Tangiers, which will specify the number of shares which the Company will sell to Tangiers. The minimum amount the Company can draw down at any one time is $5,000, and the maximum amount the Company can draw down at any one time is $350,000 as determined by the formula contained in the equity line agreement. A closing will occur on the date which is no earlier than five trading days following, and no later than seven trading days following, the applicable put notice. On each closing date, the Company will sell, and Tangiers will purchase, the shares of the Company’s common stock specified in the put notice. The amount to be paid by Tangiers on a particular closing date will be determined by multiplying the purchase price by the number of shares specified in the put notice. The purchase price is 85% of the average of the two lowest trading prices of the Company’s common stock during the pricing period applicable to the put notice. The pricing period, with respect to a particular put notice, is five consecutive trading days including, and immediately following, the delivery of a put notice to Tangiers. The Company may submit a put notice once every ten trading days provided the closing of the previous transaction has taken place. The Company is under no obligation to submit any put notices. The equity line agreement has a term of 36 months, which will begin on the effective date of the registration statement, which the Company has agreed to file with the Securities and Exchange Commission so that the shares of common stock to be sold to Tangiers may be sold in the public market. The Company issued a promissory note to Tangiers for the principal sum of $35,000 as a commitment fee for the equity line. The note bears interest at 10% per year, is unsecured, and is due and payable on July 8, 2017. The note is recorded on our consolidated balance sheet at December 31, 2016 in the amount of $35,000, net of a discount of $34,453. At the option of Tangiers, all or any part of the unpaid principal amount of the note may be converted into shares of the Company’s common stock. The number of shares to be issued on any conversion will be determined by dividing the principal amount of the note to be converted by $1.00. Clinical Trial Agreement Under the terms of an agreement dated November 11, 2017, we committed to cover the costs to perform clinical trials with The University of the West Indies through the Topical Metabolism Research Unit of the Caribbean Institute for Health Research located in Kingston, Jamaica, initially scheduled as follows: · An instalment of $50,000 upon both the approval of specific protocol by the Ethics Committee of the Institutional Review Board of the Ministry of Health, Jamaica, and the execution of the clinical trial agreement, · An instalment of $51,182 upon the enrollment of the 12 th · An instalment of $51,182 after all twelve patients go through the washout period determined in the specific protocol and return for a second dose, and · An instalment of $51,182 upon completion of the clinical trial. Additionally, we have agreed to reimburse The University of the West Indies for care and treatment of adverse reactions or injury sustained by a patient, as a direct result of the clinical trial. Research Laboratory Under the terms of a research agreement entered into in October 2017 with the University of Florida Trustees (“UFT”), we committed to pay UFT $151,772, upon the execution of the research agreement, and $75,886 in each of the months of February 2018 and June 2018, for a total commitment of $303,544. Executive Office Lease Effective August 1, 2018, we signed a thirty-six-month lease of approximately 6,683 square feet of commercial office space in Golden, Colorado that we use as our executive offices. The lease expires on July 31, 2020 and requires the payment of monthly base rental rates of $3,302 through July 31, 2018, $3,000 through July 31, 2019 and $3,799 through July 31, 2020. As additional rent, we are required to pay for an allocation of common area costs and expenses, plus all utilities. Weldona Facility Lease Effective October 1, 2017, we entered into a lease of approximately 40,000 square feet of industrial space in Weldona, Colorado that we us as our hemp extraction facility and hemp cultivation center. The term of the lease expires on October 31, 2018, with an annual option to renew that expires on September 30, 2022. The rent is $7,500 per month throughout the term of the lease, plus we are responsible for all utilities. Legal Proceedings There have been no material developments in legal proceedings in which we are involved during the year ended December 31, 2017.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 20 – SUBSEQUENT EVENTS Subsequent to June 30, 2018, we received $1,833,026 under the terms of the equity line of credit agreement with Tangiers Global, LLC from the sale of 3,401,719 shares of our common stock to Tangiers. On July 25, 2018, we repriced the exercise price per share from $1.08 to $0.58 per share for stock options to purchase 6,000,000 shares of our common stock that were granted on March 28, 2018 and repriced the exercise price per share from $0.705 to $0.58 per share for stock options to purchase 14,195,000 of our common stock that were granted on June 29, 2018. No adjustment to shared-based compensation in the consolidated financial statements for the three and six months ended June 30, 2018 was necessary as a result of the repricing of the stock options. On August 3, 2018, our 95% owned subsidiary, Prana Therapeutics, Inc. (“PTI”) received approval of an Investigational New Drug (“IND”) application from the Department of Health and Human Services’ Food and Drug Administration for a clinical investigation for breast cancer of PTI’s licensed flagship product, Epidiferphane™ (EDP™). We have committed to spend approximately $300,000 to fund phase I and phase II clinical trials in connection with the IND approval. In accordance with ASC 855-10 we have analyzed our operations subsequent to June 30, 2018 to the date these consolidated financial statements were issued, and have determined that, other than as disclosed above, we do not have any material subsequent events to disclose in these consolidated financial statements.	NOTE 20 – SUBSEQUENT EVENTS JSJ Convertible Note In accordance with ASC 855-10 we have analyzed the Company’s operations subsequent to December 31, 2017 to the date these consolidated financial statements were issued, and has determined that, other that as disclosed above, we do not have any material subsequent events to disclose in these consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN31

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation At March 31, 2017, we concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017. PTI was purchased on July 14, 2017, and their assets and liabilities are included in the consolidated balance sheets at December 31, 2017, and their results of operations are included in the consolidated financial statements for the period of June 30, 2017, which is the nearest quarter end to the purchase date, through December 31, 2017.	Principles of Consolidation
Use of Estimates	Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.	Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at June 30, 2018, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the six-month period ended June 30, 2018 and the year ended December 31, 2017.	Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at December 31, 2016, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the years ended December 31, 2017 and 2016.
Cash and Cash Equivalents	Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable, Net	Accounts Receivable Our allowance for doubtful accounts was $0.00 and $30,000 as of December 31, 2017 and 2016, respectively. We recorded bad debt expense, included in general and administrative expenses, of $0.00 and $82,831 during the years ended December 31, 2017 and 2016, respectively.
Prepaid Expenses		Prepaid Expenses -
Inventory	Inventory –	Inventory –
Property and Equipment	Property, Plant and Equipment, net	Property and Equipment December 31, 2017 2018 Conduction in process - extraction facilities Weldona, Colorado extraction facility: Equipment $ 647,947 $ — Leasehold improvements — — Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 — Leasehold improvements - cultivation 109,750 — $ 832,697 $ — Cultivation facility and laboratory equipment and Office furniture and fixtures Golden, Colorado hemp laboratory - equipment $ 34,651 — Golden, Colorado administrative offices: Furniture and fixtures 21,668 — Leasehold improvements 2,000 — Transportation equipment 81,667 — Remote laboratory equipment 99,220 — 239,206 — Accumulated amortization and depreciation (39,385 ) — $ 199,821 $ —
Granted Patents	Granted Patents. Net –	Granted Patents –
Intangible Assets	Intangible Assets –	Intangible Assets –
Long-Lived Assets Impairment Assessment	Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of June 30, 2018 or December 31, 2017.	Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of December 31, 2017 or December 31, 2016.
Equity Method Investments		Equity Method Investments
Goodwill	Goodwill	Goodwill
Purchase Price Allocation	Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures	Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures
Deferred Revenue	Deferred Revenue	Deferred Revenue
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Revenue from Contracts with Customers.	Revenue Recognition - Revenue Recognition Revenue for services with a payment in the form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue paid for with warrants is measured using the Black-Scholes-Merton pricing model. Revenue from product sales, including delivery fees, is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Reimbursable expenses, including those relating to travel, other out-of-pocket expenses and any third-party costs, are included as a component of revenues. Typically, an equivalent amount of reimbursable expenses is included in cost of revenues. Reimbursable expenses related to time and materials and fixed-fee engagements are recognized as revenue in the period in which the expense is incurred and collectability is reasonably assured. Taxes collected from customers and remitted to governmental authorities are presented in our consolidated statement of operations on a net basis. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Prana Revenue Recognition.
Cost of Revenues	Cost of Revenues	Cost of Revenues
Research and Development Expenses	Research and Development Expenses	Research and Development Expenses -
General and Administrative Expenses	General and Administrative Expenses	General and Administrative Expenses -
Stock-Based Compensation	Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation	Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the year ended year-ended December 31, 2017 or the six months ended June 30, 2018.	Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the year ended year-ended December 31, 2017.
Commitments and Contingencies	Commitments and Contingencies – Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.	Commitments and Contingencies If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Net Loss Per Share	Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Warrants to purchase common stock 25,002 1,549,112 1,259,029 1,549,112 Stock options 13,250,000 3,680,000 25,080,000 6,580,000 13,275,002 5,229,112 26,339,029 8,129,112	Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Years Ended December 31, 2017 2016 Warrants to purchase common stock 674,336 666,667 Cashless warrants exercisable and not converted to common stock 534,689 844,689 Stock options 6,637,500 3,680,000 Total potentially dilutive securities 7,846,525 5,191,356
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss)
Segment Reporting		Segment Reporting –
Concentration of Credit Risk	Concentration of Credit Risk	Concentration of Credit Risk The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Years Ended December 31, 2017 2016 Customer A 98 % 95 % Customer B 2 % 3 % Customer C — % 2 % Percentage of Accounts Receivable: Years Ended December 31, 2017 2016 Customer D — % 75 % Customer E — % 25 % Customer F 100 % — %
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures.	Recently Issued Accounting Pronouncements In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five-step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective at the beginning of fiscal year 2018, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We implemented this accounting treatment beginning January 1, 2018. In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures.
Reclassification	Reclassification

SUMMARY OF SIGNIFICANT ACCOUN32

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Warrants to purchase common stock 25,002 1,549,112 1,259,029 1,549,112 Stock options 13,250,000 3,680,000 25,080,000 6,580,000 13,275,002 5,229,112 26,339,029 8,129,112	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Years Ended December 31, 2017 2016 Warrants to purchase common stock 674,336 666,667 Cashless warrants exercisable and not converted to common stock 534,689 844,689 Stock options 6,637,500 3,680,000 Total potentially dilutive securities 7,846,525 5,191,356

RECEIVABLE FROM RELATED PARTY (

RECEIVABLE FROM RELATED PARTY (Tables)	12 Months Ended
	Dec. 31, 2017
Receivable From Related Party Tables Abstract
Schedule of Amounts Due From Related Parties	Amounts due from related parties consist of: December 31, 2017 2016 Advesa, Inc. $ — $ 21,775 Cannabinoid Research & Development, Limited — 5,000 $ — $ 26,775

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Operating Leases Tables Abstract
Schedule of Operating Leases	Future minimum payments for these leases are: For the twelve Months Ending June 30, 2019 2020 2021 2021 2022 $131,804 $135,296 $93,801 $90,001 $45,001	Future minimum payments for these leases are: For the twelve Months Ending December 31, 2018 2019 2020 2021 2022 $130,613 $133,499 $116,597 $90,000 $67,500

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Inventory Tables Abstract
Schedule of Inventory	At June 30, 2018 and December 31, 2017, our inventory is, as follows: June 30, December 31, 2018 2017 Industrial hemp crop under cultivation $ 1,391,306 $ 15,000 Raw materials 239,030 — Work-in-process — — Finished goods 13,880 28,200 $ 1,644,216 $ 43,200	At December 31, 2017, and 2016, our inventory was, as follows: December 31, 2017 2016 Raw materials $ 15,000 $ — Work-in-process — — Finished goods 28,200 — $ 43,200 $ —

PROPERTY, PLANT AND EQUIPMENT36

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
Schedule of Property and Equipment	June 30, December 31, 2018 2017 Cost of construction in process - extraction facility Weldona, Colorado extraction facility: Equipment $ — $ 647,947 Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 75,000 Leasehold improvements - cultivation 110,699 109,750 $ 185,699 $ 832,697 Extraction facility, laboratory equipment, and office furniture and fixtures Equipment and machinery at Weldona extraction facility $ 1,120,945 — Golden, Colorado industrial hemp laboratory - equipment 39,944 34,651 Golden, Colorado administrative offices: Furniture and fixtures 49,282 21,668 Leasehold improvements 191,518 2,000 Transportation equipment 191,704 81,667 Remote laboratory equipment 99,220 99,220 Farm Equipment 247,456 — $ 1,940,069 239,206 Accumulated amortization and depreciation (191,897 ) (39,385 ) $ 1,748,172 $ 199,821	December 31, 2017 2018 Conduction in process - extraction facilities Weldona, Colorado extraction facility: Equipment $ 647,947 $ — Leasehold improvements — — Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 — Leasehold improvements - cultivation 109,750 — $ 832,697 $ — Cultivation facility and laboratory equipment and Office furniture and fixtures Golden, Colorado hemp laboratory - equipment $ 34,651 — Golden, Colorado administrative offices: Furniture and fixtures 21,668 — Leasehold improvements 2,000 — Transportation equipment 81,667 — Remote laboratory equipment 99,220 — 239,206 — Accumulated amortization and depreciation (39,385 ) — $ 199,821 $ —

PURCHASE OF PRANA THERAPUETIC37

PURCHASE OF PRANA THERAPUETICS, INC. (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Purchase Of Prana Therapuetics Inc.Tables Abstract
Schedule of allocation of purchase price	The purchase price for PTI was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. The allocation of the purchase price was, as follows: June 30, Patents $ 52,596 Net assets 522,761 Goodwill 4,495,143 Total $ 5,070,500	Upon completion of an acquisition audit subsequent to the acquisition of Prana, it was determined that the net assets acquired as of July 14, 2017 were approximately $71,873 more than was reported in the Form 10-Q for the three and nine months ended September 30, 2017. As a result, the allocation of the purchase price, net assets and patent amounts has been restated as of December 31, 2017 compared to September 30, 2017, as follows: December 31, Reallocation September 30, Patents $ 52,596 $ — $ 52,596 Net assets 522,761 71,873 450,888 Goodwill 4,495,143 (71,873 ) 4,567,016 Total $ 5,070,500 $ — $ 5,070,500

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	Our accrued expenses consist of: December 31, 2017 2016 Accrued consulting fees $ — $ 45,000 Accrued wages and related expenses 10,184 — Accrued interest expense — 10,264 Total accrued expenses $ 10,184 $ 55,264

DEFERRED REVENUE (Tables)

DEFERRED REVENUE (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Deferred Revenue Disclosure [Abstract]
Schedule of deferred revenue	Our deferred revenue consists of: June 30, December 31, 2018 2017 Current portion $ 113,750 $ 180,000 Long term portion — 23,750 Deferred revenue $ 113,750 $ 203,750	Our deferred revenue consists of: December 31, 2017 2016 Deferred revenue – WeedMD $ 203,750 $ 383,750 Less – current portion (180,000 ) (180,000 ) Deferred revenue, net of current portion $ 23,750 $ 203,750

CONVERTIBLE NOTE PAYABLE (Table

CONVERTIBLE NOTE PAYABLE (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
CONVERTIBLE NOTE PAYABLE [Abstract]
Schedule of convertible promissory notes	The following table summarizes our convertible promissory notes outstanding, as of June 30, 2018 and December 31, 2017: Issue Holder Security Maturity Interest Base June 30, December 31, 4-02-18 Tangiers Global Unsecured 10-04-18 5% Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holders election to convert $ 600,000 $ — 6-04-18 Tangiers Global Unsecured 12-04-18 5% Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holders election to convert 288,750 — Less unamortized Discount (26,931 ) — $ 861,819 $ —	The following table summarizes our convertible promissory notes outstanding as of December 31, 2017 and 2016: Maturity Interest Base December 31, Issue Date Holder Security Date Rate Conversion Rate 2017 2016 12/28/2016 Tangiers Investment Group Unsecured 7/8/2017 10 % $1.00 through maturity; 55% of lowest closing price thereafter $ — $ 35,000 8/10/2016 JSJ Investments Unsecured 5/10/2017 12 % $0.20 during first 180 days; 45% of lowest closing price thereafter — 125,000 — 160,000 Less unamortized discount — (34,453 ) $ — $ 125,547

NOTES PAYABLE TO AND ADVANCES41

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS (Tables) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Notes Payable To And Advances From Officers And Directors Tables Usd
Notes payable to and advance from officers and directors	Notes payable to and advance from officers and directors consisted of the following: June 30, December 31, 2018 2017 Note payable to Earnie Blackmon, an officer and director $ 745,945 $ 246,458 Note payable to Tony Verzura, an officer and director 16,644 14,889 $ 762,589 $ 261,347	Notes payable to and advance from officers and directors consisted of the following, at December 31, 2017 and 2016: December 31, 2017 2016 Note payable to Earnie Blackmon, an officer and director $ 246,458 $ 28,750 Note payable to Tony Verzura, an officer and director 14,889 28,750 $ 261,347 $ 57,500

STOCKHOLDERS' EQUITY (DEFICIT)

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Summary of share warrants outstanding	The following table summarizes our warrants outstanding as of June 30, 2018 and December 31, 2017: June 30, December 31, 2018 2017 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,209,025 $ 0.21 $ 1,551,356 $ 0.18 Warrants issued to consultants 50,004 132,669 Warrants exercised — (475,000 ) Warrants outstanding, end of period 1,259,029 $ 0.29 1,209,025 $ 0.21 Warrants exercisable, end of period 1,259,029 $ 0.29 1,209,025 $ 0.21
Summary of stock options outstanding	The following table summarizes our stock options outstanding as of both June 30, 2018 and December 31, 2017, respectively: Number of Weighted Weighted Stock options outstanding at January 1, 2017 3,680,000 8.9 $ 0.28 Issued 3,957,500 9.9 0.64 Exercised (1,000,000 ) Expired — Stock options outstanding at December 31, 2017 6,637,500 8.7 $ 0.57 Stock options exercisable at December 31. 2017 6,637,500 8.7 0.57 Stock options outstanding at December 31, 2017 6,637,500 Issued 20,195,000 9.8 0.83 Exercised — Expired — Stock options outstanding at June 30, 2018 26,832,000 9.9 0.75 Stock options exercisable at June 30, 2018 25,080,000 9.5 $ 0.74	The following table summarizes our stock options outstanding as of both December 31, 2017 and 2016, respectively: Number of Weighted Weighted Stock options outstanding at December 31, 2015 600,000 9.8 $ 0.70 Issued 3,080,000 10.0 $ 0.20 Exercised — — — Expired — — — Stock options outstanding at December 31, 2016 3,680,000 8.9 $ 0.28 Issued 3,957,500 Exercised (1,000,000 ) Expired — Stock options exercisable at December 31, 2017 6,637,500 8.7 $ 0.57
Stock Options [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	We calculated the fair value of each option to be approximately $0.91 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 1.05 Exercise price $ 1.08 Risk free interest rate 2.8 % Expected term (years) 5-10 Expected volatility 197 % Expected dividends 0 % We calculated the fair value of each option to be approximately $0.59 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.71 Exercise price $ 0.95 Risk free interest rate 2.68 - 2.79 % Expected term (years) 5 Expected volatility 210% - 214 % Expected dividends 0 %	We calculated the fair value of each option to be approximately $0.70 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.70 Exercise price $ 0.70 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 %
Stock Incentive Plan 2014 [Member] | Stock Options [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value		We calculated the fair value of each option to be approximately $0.20 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.20 Exercise price $ 0.20 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 %
Warrant [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	666,667 warrants issued during the year ended December 31, 2017 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % 50,004 warrants issued during the six months ended June 30, 2018 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 %	Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 %
Summary of share warrants outstanding		The following table summarizes our share warrants outstanding as of December 31, 2017 and 2016: Year Ended December 31, 2017 2016 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,551,356 $ 0.18 $ 3,000,000 $ 12.00 Warrants issued to consultants 132,669 — 666,667 0.18 Cashless warrants issued upon conversion of Slainte note — — 1,584,689 — Warrants exercised (475,000 ) — (700,000 ) — Expired — — (3,000,000 ) — Warrants outstanding, end of period 1,209,025 $ 0.21 1,551,356 $ 0.18 Warrants exercisable, end of period 1,209,025 $ 0.21 1,551,356 $ 0.18

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of share-based compensation expense	Share-based compensation expense for the six months ended June 30, 2018 and 2017 is, as follows: Three Months Ended Six Months Ended 2018 2017 2018 2017 Options granted to officers, directors and employees $ 9,185,725 $ 1,624,000 $ 14,510,479 $ 1,568,000 Common stock issued for accounts payable and accrued expenses — — — 43,676 Options granted for services 26,318 — 51,320 — Warrants and options issued for consulting services — 125,826 — 217,159 Common stock issued for services 110,506 75,918 225,393 196,534 Common stock issued as compensation to employees 145,000 — 178,500 — $ 9,467,549 $ 1,825,744 $ 14,965,692 $ 2,025,369	Share-based compensation expense for the years ended December 31, 2017 and 2016 is, as follows: December 31, 2017 2016 Warrants issued for consulting and other services $ 249,835 $ 319,419 Common stock issued for accounts payable and accrued expenses 93,002 223,484 Common stock issued for services — 271,097 Common stock issued upon conversion of debt and loss on extinguishment of debt 381,576 — Common stock issued for advisory board fees 113,336 — Common stock issued as compensation to employees 170,233 — Common shares issued in settlement of dispute 102,139 — Stock options issued to officers and directors 2,660,159 — $ 3,770,279 $ 814,000

SIGNIFICANT CUSTOMER INFORMAT44

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Risks and Uncertainties [Abstract]
Schedule of significant concentrations risk	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Six Months Ended June 30, 2018 2017 Customer A 27% 50% Customer B 24% 49% Customer C 14% 1% Percentage of Accounts Receivable: As of June 30, 2018 2017 Customer C 100% —% Customer D —% —% Customer E —% —% The following tables show significant concentrations in our expenses and accounts payable for the periods indicated: Percentage of Expenses: Six Months Ended June 30, 2018 2017 Vendor A 17% —% Vendor B 14% —% Vendor C 11% —% Percentage of Accounts Payable: As of June 30, 2018 2017 Vendor C 26% —% Vendor D 17% —% Vendor E 8% —%	Percentage of Revenue: Years Ended December 31, 2017 2016 Customer A 98 % 95 % Customer B 2 % 3 % Customer C — % 2 % Percentage of Accounts Receivable: Years Ended December 31, 2017 2016 Customer D — % 75 % Customer E — % 25 % Customer F 100 % — %

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of sources and tax effects of the differences for the periods	The sources and tax effects of the differences for the periods presented are as follows: Years Ended December 31, 2017 2016 Statutory U.S. federal tax rate 39 % 39 % Effect of increase in valuation allowance (39 %) (39 %) — % — %
Schedule of changes in cumulative net deferred tax assets	Changes in our cumulative net deferred tax assets consist of the following: December 31, 2017 2016 Net loss carry-forward $ 4,923,492 $ 3,648,316 Valuation allowance (4,923,492 ) (3,648,316 ) $ — $ —
Schedule of reconciliation of income taxes computed at the statutory rate	A reconciliation of our income taxes computed at the statutory rate is as follows: Years Ended December 31, 2017 2016 Tax benefit at statutory rate $ 2,023,555 $ 1,500,068 Valuation allowance (2,023,555 ) (1,500,068 ) $ — $ —

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Commitments And Contingencies Tables
Summary of Consolidated statements of operations expense		During the years ended December 31, 2017 and 2016, we recognized in our consolidated statements of operations expenses in the total amount of $156,630 and $394,215, respectively, related to this contract, as follows: December 31, 2017 2016 Cash paid to consultant $ 30,000 $ 15,000 Fair value of shares of common stock issued to consultant 27,297 62,781 Fair value of warrants issued to consultant 99,333 319,419 $ 156,630 $ 397,200
Schedule of Future Minimum Lease Payments for Operating Leases - Executive Office Lease	Future minimum payments for this lease are: For the Twelve Months Ending June 30, 2019 2020 2021 2021 2022 $41,802 $45,295 $3,800 $0 $0

BUSINESS ORGANIZATION AND NAT47

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) - USD ($)	Jul. 14, 2017	Mar. 31, 2014	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Mar. 26, 2014
Amount of payable owed to former officer and director, exchanged for assets sold		$ 15,000
Number of common shares issued in exchange for certain intellectual property		38,690,000
Total number of common shares previously outstanding, cancelled during period								41,690,000
Common stock, shares outstanding			64,229,926		62,862,066		50,650,994	43,620,000
Business Development			$ 2,800,000
Prana [Member]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Prana [Member] | Subscription Agreement [Member]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000		$ 50,000	$ 50,000	$ 50,000	$ 50,000

SUMMARY OF SIGNIFICANT ACCOUN48

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)Item	Dec. 31, 2016USD ($)	Sep. 30, 2017USD ($)
Property, Plant and Equipment [Line Items]
Cash equivalents
Number of operating segment | Item			1
Allowance for doubtful accounts	$ 0		$ 0	30,000
Bad debt expense, included in general and administrative expenses	0		0	82,831
Goodwill	4,838,603		4,838,603
Purchase Price Allocation	5,070,500		5,070,500
Excess of purchase price over fair values of net tangible assets and intangible assets recorded as goodwill	$ 4,731,729		4,731,729
Chief Executive Officer [Member]
Property, Plant and Equipment [Line Items]
Cash equivalents			$ 0	$ 4,158
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years		5 years
Estimated useful life	15 years		15 years
Equity Method Investments, Percentage	50.00%		50.00%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years		3 years
Estimated useful life	10 years		10 years
Equity Method Investments, Percentage	20.00%		20.00%
Patents [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years		15 years
PTI [Member]
Property, Plant and Equipment [Line Items]
Equity Method Investments, Percentage	95.00%		95.00%
Goodwill	$ 4,495,143		$ 4,495,143		$ 4,567,016
Purchase Price Allocation	$ 5,070,500		$ 5,070,500		$ 5,070,500
CRD [Member]
Property, Plant and Equipment [Line Items]
Equity Method Investments, Percentage	50.00%		50.00%
Goodwill	$ 106,874		$ 106,873

SUMMARY OF SIGNIFICANT ACCOUN49

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment) (Details) - USD ($)	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Construction in process - extraction facilities		$ 185,699	$ 832,697
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross		1,940,069	239,206
Accumulated amortization and depreciation		(191,897)	(39,385)	0
Cultivation facility and laboratory equipment and Office furniture and fixtures		1,748,172	199,821
Equipment [Member] | Colorado Extraction Facility [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Construction in process - extraction facilities			647,947
Equipment [Member] | Colorado Extraction Facility [Member] | Subsequent Event [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Construction in process - extraction facilities
Leasehold Improvements [Member] | Colorado Extraction Facility [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Construction in process - extraction facilities
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross			2,000
Leasehold Improvements [Member] | Colorado Extraction Facility [Member] | Subsequent Event [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Construction in process - extraction facilities
Leasehold Improvements - Laboratory [Member] | Jamaica Cultivation and Extraction Facility [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Construction in process - extraction facilities		75,000	75,000
Leasehold Improvements - Cultivation [Member] | Jamaica Cultivation and Extraction Facility [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Construction in process - extraction facilities		110,699	109,750
Leasehold Improvements - Cultivation [Member] | Jamaica Cultivation and Extraction Facility [Member] | Subsequent Event [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Construction in process - extraction facilities
Golden, Colorado Hemp Laboratory - Equipment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross		39,944	34,651
Golden, Colorado Hemp Laboratory - Equipment [Member] | Subsequent Event [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross
Furniture and Fixtures [Member] | Colorado Extraction Facility [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross			21,668
Furniture and Fixtures [Member] | Colorado Extraction Facility [Member] | Subsequent Event [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross
Furniture and Fixtures [Member] | Colorado Extraction Facility [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross		191,704	81,667
Furniture and Fixtures [Member] | Colorado Extraction Facility [Member] | Subsequent Event [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross
Remote Laboratory Equipment [Member] | Colorado Extraction Facility [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross		$ 99,220	$ 99,220
Remote Laboratory Equipment [Member] | Colorado Extraction Facility [Member] | Subsequent Event [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cultivation facility and laboratory equipment and Office furniture and fixtures, gross

SUMMARY OF SIGNIFICANT ACCOUN50

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details) - shares	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	13,275,002	5,229,112	26,339,029	8,129,112	7,846,525	5,191,356
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	13,250,000	3,680,000	25,080,000	6,580,000	6,637,500	3,680,000
Cashless warrants not converted to common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share					534,689	844,689
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	25,002	1,549,112	1,259,029	1,549,112	674,336	666,667

SUMMARY OF SIGNIFICANT ACCOUN51

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of concentration of credit risk) (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Revenue [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	27.00%	50.00%	98.00%	95.00%
Revenue [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	24.00%	49.00%	2.00%	3.00%
Revenue [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	1.00%		2.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100.00%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage				75.00%
Accounts Receivable [Member] | Customer E [Member]
Concentration Risk [Line Items]
Concentration risk percentage				25.00%
Accounts Receivable [Member] | Customer F [Member]
Concentration Risk [Line Items]
Concentration risk percentage

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
GOING CONCERN [Abstract]
Net loss (income)	$ 10,797,690	$ 2,098,773	$ 18,004,250	$ 2,914,749	$ 5,907,512	$ 3,854,004
Net cash used in operating activities			3,830,292	$ 374,024	1,878,276	274,670
Working capital deficit					288,439
Accumulated deficit	$ 33,274,094		$ 33,274,094		$ 15,269,845	$ 9,362,333

RECEIVABLE FROM RELATED PARTY53

RECEIVABLE FROM RELATED PARTY (Narrative) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Due from related parties	$ 59,170		$ 26,775
Advesa [Member]
Related Party Transaction [Line Items]
Due from related parties	$ 59,170		$ 21,755

RECEIVABLE FROM RELATED PARTY54

RECEIVABLE FROM RELATED PARTY (Schedule of Amounts Due from Related Parties) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Apr. 30, 2015
Related Party Transaction [Line Items]
Total due from related parties	$ 59,170		$ 26,775
Advesa [Member]
Related Party Transaction [Line Items]
Total due from related parties	$ 59,170		21,755
CRD [Member]
Related Party Transaction [Line Items]
Total due from related parties			$ 5,000	$ 5,000

OPERATING LEASES (Narrative) (D

OPERATING LEASES (Narrative) (Details)	Oct. 01, 2017ft²	Aug. 01, 2017ft²	Jun. 30, 2018USD ($)a	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)a
CRD [Member]
Equity Method Investments, Percentage			50.00%				50.00%
Lease amount from father of directors and members			$ 1				$ 1
Hemp Laboratory - Golden, Colorado [Member]
Area of lease | ft²		9,882
Maturity date		Jul. 31, 2020
Hemp Laboratory - Golden, Colorado [Member] | Subsequent Event [Member]
Basic rent per month				$ 3,800	$ 3,500	$ 3,302
Colorado Extraction Facility [Member]
Area of lease | ft²	40,000
Maturity date	Sep. 30, 2018
Basic rent per month			$ 7,500			$ 7,500
Jamaica Cultivation and Extraction Facility [Member]
Area of lease | a			28				28

OPERATING LEASES (Schedule of F

OPERATING LEASES (Schedule of Future Minimum Payament) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Operating Leases
2,018		$ 130,613
2,019	$ 131,804	133,499
2,020	135,296	116,597
2,021	93,801	90,000
2,022	90,001	$ 67,500
2,023	$ 45,001

INVENTORY (Details)

INVENTORY (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Inventory Abstract
Industrial hemp crop under cultivation	$ 1,391,306
Raw materials	239,030	$ 15,000
Work-in-process
Finished goods	13,880	28,200
Inventory	$ 1,644,216	$ 43,200

PROPERTY, PLANT AND EQUIPMENT58

PROPERTY, PLANT AND EQUIPMENT, NET (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 52,055	$ 3,329	$ 156,098	$ 12,079	$ 40,161

PROPERTY, PLANT AND EQUIPMENT59

PROPERTY, PLANT AND EQUIPMENT, NET (Schedule of Property and Equipment) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	$ 185,699	$ 832,697
Extraction facility, laboratory equipment, and office furniture and fixtures	1,940,069	239,206
Accumulated amortization and depreciation	(191,897)	(39,385)	0
Cultivation facility and laboratory equipment and Office furniture and fixtures	1,748,172	199,821
Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility		647,947
Leasehold Improvements - Laboratory [Member] | Jamaica Cultivation and Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	75,000	75,000
Leasehold Improvements - Cultivation [Member] | Jamaica Cultivation and Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	110,699	109,750
Equipment and machinery at Weldona extraction facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	1,120,945
Golden, Colorado Industrial Hemp Laboratory - Equipment [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	39,944	34,651
Furniture and Fixtures [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures		21,668
Furniture and Fixtures [Member] | Colorado Administrative Offices [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	49,282	21,668
Leasehold Improvements [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility
Extraction facility, laboratory equipment, and office furniture and fixtures		2,000
Leasehold Improvements [Member] | Colorado Administrative Offices [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	191,518	2,000
Furniture and Fixtures [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	191,704	81,667
Remote Laboratory Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	99,220	99,220
Farm Equipment [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	$ 247,456

PURCHASE OF PRANA THERAPUETIC60

PURCHASE OF PRANA THERAPUETICS, INC. (Narrative) (Details) - Prana [Member] - USD ($)	Jul. 14, 2017	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Business Acquisition [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Shares issued in acquisition	400,000
Shares issued in acquisition, value	$ 200,000
Net assets acquired					$ 164,713
Subscription Agreement [Member]
Business Acquisition [Line Items]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000

PURCHASE OF PRANA THERAPUETIC61

PURCHASE OF PRANA THERAPUETICS, INC. (Schedule of Purchase Price Allocation) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 4,838,603	$ 4,838,603
Purchase Price Allocation	5,070,500	5,070,500
PTI [Member]
Business Acquisition [Line Items]
Patents	52,596	52,596	$ 52,596
Net assets	522,761	522,761	450,888
Goodwill	4,495,143	4,495,143	4,567,016
Purchase Price Allocation	$ 5,070,500	5,070,500	$ 5,070,500
Reallocation of Purchase Price[Member]
Business Acquisition [Line Items]
Patents
Net assets		71,873
Goodwill		(71,873)
Purchase Price Allocation

GRANTED PATENT (Details)

GRANTED PATENT (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Aug. 15, 2017
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization		$ 2,679	$ 0
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful live	15 years	15 years
Amortization expense	$ 3,558	$ 2,679	0
Accumulated amortization	$ 6,237	$ 2,679	$ 0
Research, legal fees				$ 142,317

INTANGIBLES (Details)

INTANGIBLES (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	15 years	15 years
Design Marks and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years	10 years

EQUITY METHOD INVESTMENTS (Narr

EQUITY METHOD INVESTMENTS (Narrative) (Details) - USD ($)	Aug. 15, 2014	Dec. 31, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Equity method investments			$ 88,000
CRD [Member]
Schedule of Equity Method Investments [Line Items]
Interest acquired (as a percentage)	50.00%
Equity method investments	$ 88,000
Shares of common stock issuable for acquisition of interest	40,000

ACCRUED EXPENSES (Narrative) (D

ACCRUED EXPENSES (Narrative) (Details) - USD ($)	May 06, 2014	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2015
Costs recognized		$ 379,579	$ 215,386	$ 642,825	$ 456,200	$ 878,257	$ 643,913
Accrued expenses		24,875		24,875		10,184	55,264
Loss on extinguishment of debt					$ 267,567	$ 248,892	$ 691,904
Research and Development Arrangement [Member]
Consultancy agreement, term	9 months
Consultancy agreement, initial payment	$ 50,000
Consultancy agreement, additional payments	50,000
Consultancy agreement, total payments	$ 200,000
Shares issued for consultancy agreement	100,000						100,000
Costs recognized								$ 160,000
Accrued expenses									$ 110,000
Percentage of completion									80.00%
Fair value of shares							$ 163,783
Loss on extinguishment of debt							$ 53,783

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Accrued consulting fees			$ 45,000
Accrued wages and related expenses		10,184
Accrued interest expense			10,264
Total accrued expenses	$ 24,875	$ 10,184	$ 55,264

INSTALLMENT LOANS PAYABLE (Deta

INSTALLMENT LOANS PAYABLE (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Short-term Debt [Line Items]
Installment loan payable	$ 94,607	$ 46,667
Installment loan monthly payment		972
Monthly payments being made to pay off loan in six months		7,778
Installment One [Member]
Short-term Debt [Line Items]
Installment loan monthly payment	955
Monthly payments being made to pay off loan in six months	$ 6,955
Term period	48 months
Installment Two [Member]
Short-term Debt [Line Items]
Installment loan monthly payment	$ 2,160
Monthly payments being made to pay off loan in six months	$ 6,500
Term period	36 months
48 Month Installment [Member]
Short-term Debt [Line Items]
Installment loan payable	$ 17,892	46,667
36 Month Installment [Member]
Short-term Debt [Line Items]
Installment loan payable	$ 76,715	$ 0

DEFERRED REVENUE (Narrative) (D

DEFERRED REVENUE (Narrative) (Details) - USD ($)	Jun. 09, 2014	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2014	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2019	Dec. 30, 2014
Deferred Revenue Arrangement [Line Items]
Deferred revenue		$ 113,750			$ 203,750	$ 383,750
Less - current portion		(113,750)			(180,000)	(180,000)
Deferred revenue, net of current portion					23,750	203,750
WeedMD RX Inc. (''WMD'') [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue		113,750			203,750	383,750
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000
Fair value of securities recorded as deferred revenue	$ 893,750
Deferred revenue recognized per month		15,000			15,000
Total deferred revenue recognized		$ 90,000	$ 90,000	$ 150,000	$ 180,000	180,000
Deffered income recognized other income						200,000
WeedMD RX Inc. (''WMD'') [Member] | Subsequent Event [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue							$ 135,750
Fox Barry Farms Llc [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue								$ 200,000

DEFERRED REVENUE (Schedule of d

DEFERRED REVENUE (Schedule of deferred revenue) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred Revenue Disclosure [Abstract]
Current portion	$ 113,750	$ 180,000	$ 180,000
Long term portion		23,750	203,750
Deferred revenue	$ 113,750	$ 203,750	$ 383,750

CONVERTIBLE NOTES PAYABLE (Narr

CONVERTIBLE NOTES PAYABLE (Narrative) (Details) - USD ($)	Aug. 10, 2016	Jul. 05, 2016	Apr. 06, 2016	Mar. 31, 2016	Mar. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Net cash proceeds received from initial borrowing						$ 845,000			$ 316,478
Loss on origination of derivative liability									(1,894,258)
Components of convertible debt, net
Amortization of debt discount						16,819	34,453	30,453	267,258
Proceeds from debt, net						$ 501,241	$ 245,286	254,942	50,000
Advances from officers and directors								77,384	71,008
2015 Convertible Notes [Member]
Debt Instrument [Line Items]
Number of trading days immediately preceding the applicable conversion										180 days
Components of convertible debt, net
Holding rate of issued and outstanding common stock										9.99%
2016 Convertible Notes [Member]
Components of convertible debt, net
Interest expense								30,543	35,719
Aggregate fair value of the derivative liabilities									$ 557,000
Accured interest converted in common stock									497,296
SlainteVentures, LLC [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate		12.00%
Components of convertible debt, net
Accrued interest payable			$ 102,000
Proceeds from debt, net		$ 50,000	75,000		$ 81,978
Advances from officers and directors			$ 52,500
Minimum [Member] | 2015 Convertible Notes [Member]
Components of convertible debt, net
Prepayment premiums										10.00%
Minimum default penalty amount, rate										25.00%
Maximum [Member] | 2015 Convertible Notes [Member]
Components of convertible debt, net
Prepayment premiums										40.00%
Minimum default penalty amount, rate										50.00%
JSJ Investments [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	12.00%
Components of convertible debt, net
Proceeds from debt, net	$ 125,000
Average closing price of common stock	$ 0.20
Conversions rate on issue and outstandng common stock	4.99%
Vis Vires Group, Inc. [Member] | SlainteVentures, LLC [Member]
Components of convertible debt, net
Minimum default penalty amount, rate									15.00%
Repayment of principal and accrued interest				$ 59,000
Average closing price of common stock									$ 0.45
Tangiers Convertible Note [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate									10.00%
Expiration date									Jul. 8, 2017
Components of convertible debt, net
Proceeds from debt, net									$ 35,000
Debt Instrument Fair Value of Warrants Issued Recorded as Unamortized Discount
Debt Instrument [Line Items]
Debt instrument, interest rate	12.00%
Net cash proceeds received from initial borrowing	$ 125,000
Typenex Co Investment Llc [Member] | Convertible Note [Member]
Debt Instrument [Line Items]
Debt instrument initial borrowing										$ 381,000
Components of convertible debt, net
Accrued interest payable								$ 0	$ 5,876
Tangiers Global [Member] | Convertible Note [Member]
Components of convertible debt, net
Number of Common shares converted									2,843,698

CONVERTIBLE NOTES PAYABLE (Sche

CONVERTIBLE NOTES PAYABLE (Schedule of convertible promissory notes issued) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 30, 2016
Maturity Date		Jul. 8, 2017
Total principal outstanding			$ 160,000
Less unamortized discount	$ (26,931)		(34,453)
Total of outstanding amount	$ 861,819		125,547
Tangiers Global [Member] | 2016 Convertible Notes [Member]
Issue Date		Dec. 28, 2016
Holder		Tangiers Global
Security		Unsecured
Maturity Date		Jul. 8, 2017
Interest Rate		10.00%
Base Conversion Rate		1.00 through maturity; 55% of lowest closing price thereafter
Total principal outstanding			35,000
Tangiers Global [Member] | 2018 Convertible Notes [Member]
Issue Date	Apr. 2, 2018
Holder	Tangiers Global
Security	Unsecured
Maturity Date	Oct. 4, 2018
Interest Rate	5.00%
Base Conversion Rate	Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holders election to convert
Total principal outstanding	$ 600,000
Tangiers Global [Member] | 2018 Convertible Notes [Member]
Issue Date	Jun. 4, 2018
Holder	Tangiers Global
Security	Unsecured
Maturity Date	Dec. 4, 2018
Interest Rate	5.00%
Base Conversion Rate	Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holders election to convert
Total principal outstanding	$ 288,750
JSJ Investments Inc. [Member]
Interest Rate				12.00%
JSJ Investments Inc. [Member] | 2016 Convertible Notes [Member]
Issue Date		Aug. 10, 2016
Holder		JSJ Investments
Security		Unsecured
Maturity Date		May 10, 2017
Interest Rate		12.00%
Base Conversion Rate		$0.20 during first 180 days; 45% of lowest closing price thereafter
Total principal outstanding			$ 125,000

NOTES PAYABLE TO AND ADVANCES72

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS (Narrative) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 30, 2016	Apr. 06, 2016	Oct. 12, 2015
Related Party Transaction [Line Items]
Debt repayment terms	If the loans are repaid on or before September 30, 2016, the principal amount, which is being repaid, will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount, which is being repaid will increase by 15%.
Notes payable to and advances from officers and directors	$ 473,516
Earnie Blackmon [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	745,945	$ 246,458	$ 28,750
Tony Verzura [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount					$ 25,000
Tony Verzura [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	16,644	14,889	28,750
Accrued wages payable to officers and directors [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	$ 762,589	$ 261,347	$ 57,500
Ernest Blackmon [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount					$ 25,000
Debt Instrument Fair Value of Warrants Issued Recorded as Unamortized Discount
Related Party Transaction [Line Items]
Convertible note payable, related party						$ 102,000
JSJ Investments Inc. [Member]
Related Party Transaction [Line Items]
Debt instrument, interest rate				12.00%

ARBITRATION SETTLEMENT RESERVE

ARBITRATION SETTLEMENT RESERVE (Details) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Loss Contingency [Abstract]
Arbitration settlement reserve	$ 650,000
Proceeds from proposed joint venture that was never formed	650,000
Amount of refund	$ 650,000

STOCKHOLDERS' EQUITY (DEFICIT74

STOCKHOLDERS' EQUITY (DEFICIT) (Narrative) (Details) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Jul. 18, 2017	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Proceeds from shares issued			$ 208,982
Aggregate intrinsic value of warrants outstanding and exercisable			$ 0
Warrant issued		50,004	132,669	666,667
Warrant [Member]
Warrant issued		50,004	666,667	83,333
Weighted-average remaining contractual life for stock options outstanding and exercisable		3 years 7 months 6 days
Preferred Class A [Member] | Officer and Director [Member]
Share issued	2,000
Proceeds from shares issued	$ 2,200

STOCKHOLDERS' EQUITY (DEFICIT75

STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock Issued For Services, Warrants) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Warrants outstanding, beginning of period	1,209,025	1,551,356	3,000,000
Warrants issued to consultant	50,004	132,669	666,667
Cashless issued upon conversion of Slainte note			1,584,689
Warrants exercised		(475,000)	(700,000)
Expired (in shares)			(3,000,000)
Warrants outstanding, end of period	1,259,029	1,209,025	1,551,356
Warrants exercisable at the end of the period (in shares)	1,259,029	1,209,025	1,551,356
Weighted Average Remaining Life (years)
Warrants exercisable at the end of the period		3 years
Weighted Average Exercise Price
Warrants outstanding, beginning of period (in dollars per share)	$ 0.21	$ 0.18	$ 12
Issued (in dollars per share)			0.18
Exercised (in dollars per share)
Expired (in dollars per share)
Warrants outstanding, end of period (in dollars per share)	0.29	0.21	0.18
Warrants exercisable at the end of the period (in dollars per share)	$ 0.29	$ 0.21	$ 0.18

STOCKHOLDERS' EQUITY (DEFICIT76

STOCKHOLDERS' EQUITY (DEFICIT) (Schedule of Assumptions on Date of Valuation Utilizing for Fair Value of Warrants) (Details) - $ / shares	Jan. 12, 2016	Jan. 09, 2015	Feb. 28, 2018	Jun. 30, 2018	Dec. 31, 2017
Warrant [Member]
Exercise price (in dollars per share)				$ 0.18
Expected term (years)				5 years
Expected dividends (as a percent)				0.00%
Warrant [Member] | Minimum [Member]
Stock price (in dollars per share)				$ 0.16	$ 0.16
Risk free interest rate (as a percent)				1.01%	1.01%
Expected term (years)					5 years
Expected volatility (as a percent)				322.00%	322.00%
Warrant [Member] | Maximum [Member]
Stock price (in dollars per share)				$ 2.18	$ 2.18
Risk free interest rate (as a percent)				1.37%	1.37%
Expected volatility (as a percent)				504.00%	504.00%
Stock Options [Member]
Stock price (in dollars per share)	$ 0.20	$ 0.70	$ 1.05	$ 0.71
Exercise price (in dollars per share)	$ 0.20	$ 0.70	$ 1.08	$ 0.95
Risk free interest rate (as a percent)	1.98%	1.98%	2.80%
Expected term (years)	10 years	10 years		5 years
Expected volatility (as a percent)	173.00%	173.00%	197.00%
Expected dividends (as a percent)	0.00%	0.00%	0.00%	0.00%
Stock Options [Member] | Minimum [Member]
Risk free interest rate (as a percent)				2.68%
Expected term (years)			5 years
Expected volatility (as a percent)				210.00%
Stock Options [Member] | Maximum [Member]
Risk free interest rate (as a percent)				2.79%
Expected term (years)			10 years
Expected volatility (as a percent)				214.00%

STOCKHOLDERS' EQUITY (DEFICIT77

STOCKHOLDERS' EQUITY (DEFICIT) (Schedule of stock option activity) (Details) - Stock Options [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares
Stock options outstanding, beginning of period	6,637,500	3,680,000	600,000
Issued	20,195,000	3,957,500	3,080,000
Exercised		(1,000,000)
Expired
Stock options outstanding, end of period	26,832,000	6,637,500	3,680,000	600,000
Stock options exercisable, end of period	25,080,000
Weighted Average Exercise Price
Stock options outstanding, beginning of period	$ 0.57	$ 0.28	$ 0.70
Issued	0.83	0.64	0.20
Exercised
Expired
Stock options outstanding, end of period	0.75	0.57	$ 0.28	$ 0.70
Stock options exercisable, end of period	$ 0.74	$ 0.57
Weighted Average Remaining Life (Years)
Stock options outstanding, beginning of period	8 years 8 months 12 days	8 years 10 months 25 days	8 years 1 month 2 days	9 years 9 months 18 days
Stock options Issued, end of period	9 years 9 months 18 days	9 years 10 months 25 days	10 years
Stock options outstanding, end of period	9 years 10 months 25 days	8 years 8 months 12 days
Stock options exercisable, end of period	9 years 6 months	8 years 8 months 12 days

STOCKHOLDERS' EQUITY (DEFICIT78

STOCKHOLDERS' EQUITY (DEFICIT) (Stock Option Activity) (Narrative) (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 29, 2018	Jun. 25, 2018	Feb. 28, 2018	Jan. 12, 2016	Dec. 31, 2015	Jan. 12, 2015	Jan. 09, 2015	Dec. 31, 2014
Stock options compensation			$ 2,660,159
Stock Options [Member]
Awarded stock options	$ 14,195,000	$ 14,195,000						$ 1,050,000
Fair value of options	6,146,000	6,146,000			9,711,400			612,512				417,664
Weighted-average remaining contractual life for stock options outstanding and exercisable		9 years 6 months	8 years 8 months 12 days
Aggregate intrinsic value of options outstanding and exercisable	$ 1	$ 1	$ 0
Option vested	5,125,000	5,125,000
Stock options compensation	$ 9,053,341	$ 5,324,754
Total price to exercise all outstanding stock options	$ 14,301,000	$ 14,301,000
Stock options to purchase common stock		6,000,000
Stock options	26,832,000	26,832,000	6,637,500	3,680,000					600,000
Stock Options [Member] | Minimum [Member]
Exercise price					$ 0.705	$ 1.08
Stock Options [Member] | Maximum [Member]
Exercise price					$ 0.58	$ 0.58
Stock Options [Member] | Vesting through December 31, 2019 [Member]
Option vested	875,000	875,000
Stock Options [Member] | Vesting quarterly through July 1, 2022 [Member]
Option vested	945,000	945,000
2014 Stock Incentive Plan [Member]
Awarded stock options											$ 200,000
2014 Stock Incentive Plan [Member] | Mr. Ruby [Member]
Awarded stock options										$ 980,000
Common stock, per share value										$ 0.20
2017 Stock Incentive Plan [Member]
Awarded stock options							$ 6,000,000
Stock Incentive Plan 2018 [Member] | Stock Options [Member]
Awarded stock options	$ 14,195,000	$ 14,195,000
Option vested	13,250,000	13,250,000

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options granted to officers, directors and employees	$ 9,185,725	$ 1,624,000	$ 14,510,479	$ 1,568,000
Common stock issued for accounts payable and accrued expenses				43,676	$ 93,002	$ 223,484
Options granted for services	26,318		51,320
Warrants and options issued for consulting services		125,826		217,159
Common stock issued for services	110,506	75,918	225,393	196,534		271,097
Common stock issued as compensation to employees	145,000		178,500		170,233
Warrants issued for consulting and other services					249,835	319,419
Common stock issued for advisory board fees					113,336
Stock options issued to officers and directors					2,660,159
Share-based compensation	$ 9,467,549	$ 1,825,744	$ 14,965,692	$ 2,025,369	$ 3,286,565	$ 814,000

SIGNIFICANT CUSTOMER INFORMAT80

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY (Schedule of concentration of risk) (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Revenue [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	27.00%	50.00%	98.00%	95.00%
Revenue [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	24.00%	49.00%	2.00%	3.00%
Revenue [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	1.00%		2.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100.00%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage				75.00%
Accounts Receivable [Member] | Customer E [Member]
Concentration Risk [Line Items]
Concentration risk percentage				25.00%
Expenses [Member] | Vendor A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	17.00%
Expenses [Member] | Vendor B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14.00%
Expenses [Member] | Vendor C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	11.00%
Accounts Payable [Member] | Vendor C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	26.00%
Accounts Payable [Member] | Vendor D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	17.00%
Accounts Payable [Member] | Vendor E [Member]
Concentration Risk [Line Items]
Concentration risk percentage	8.00%

INCOME TAXES (Schedule of Sourc

INCOME TAXES (Schedule of Sources and Tax Effects of Differences for Periods) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Sources and tax effects of the differences
Statutory U.S. federal tax rate	39.00%	39.00%
Effect of increase in valuation allowance	(39.00%)	(39.00%)

INCOME TAXES (Schedule of Chang

INCOME TAXES (Schedule of Changes in Cumulative Net Deferred Tax Assets) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Net deferred tax assets
Net loss carry forward	$ 4,923,492	$ 3,648,316
Valuation allowance	(4,923,492)	(3,648,316)
Net deferred tax assets

INCOME TAXES (Schedule of Recon

INCOME TAXES (Schedule of Reconciliation of Income Taxes Computed at Statutory Rate) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of income taxes computed at statutory rate
Tax benefit at statutory rate					$ 2,023,555	$ 1,500,068
Valuation allowance					(2,023,555)	(1,500,068)
Income tax expense (benefit)

COMMITMENTS AND CONTINGENCIES84

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 20, 2016USD ($)$ / sharesshares	Jun. 30, 2018USD ($)ft²	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)ft²shares	Jun. 30, 2017USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2017USD ($)ft²	Dec. 31, 2016USD ($)	Jan. 19, 2018USD ($)	Oct. 31, 2017USD ($)	Dec. 28, 2016USD ($)
Long-term Purchase Commitment [Line Items]
Research and development		$ 241,547	$ 4,235	$ 478,225	$ 49,395			$ 293,968	$ 23,124
Commitment fee								$ 35,000
Bear Note interest per year								10.00%
Maturity Date								Jul. 8, 2017
Note payable								$ 34,453
Net discount		$ 26,931		26,931					34,453
Minimum amount draw down at one time				$ 5,000				5,000
Percentage of number of common shares				400.00%
Maximum amount draw down at one time				$ 1,000,000				$ 350,000
Percentage of trading price				85.00%				85.00%
Prana [Member]
Long-term Purchase Commitment [Line Items]
Total commitment upon execution of research agreement											$ 151,772
Commitment owed in February 2018											75,886
Commitment owed in June 2018											75,886
Total commitment amount owed											$ 303,544
Executive Office Lease [Member]
Long-term Purchase Commitment [Line Items]
Lease term				36 months				36 months
Lease Space | ft²		6,683		6,683				6,683
Lease Expires				Jul. 31, 2020				Jul. 31, 2020
Monthly rental rates				$ 3,302				$ 3,302
2,018		$ 41,802		41,802
2,019		45,295		45,295
2,020		3,800		3,800
2,021		0		0
2,022		$ 0		$ 0
Executive Office Lease [Member] | Subsequent Event [Member]
Long-term Purchase Commitment [Line Items]
Monthly rental rates						$ 3,799	$ 3,000
Weldona Facility Lease [Member]
Long-term Purchase Commitment [Line Items]
Lease Space | ft²								40,000
Lease Expires								Sep. 30, 2022
Monthly rental rates								$ 7,500
Extraction Facility Lease [Member]
Long-term Purchase Commitment [Line Items]
Lease Space | ft²		40,000		40,000
Lease Expires				Sep. 30, 2022
Monthly rental rates				$ 7,500
Industrial Hemp Crop Under Cultivation [Member]
Long-term Purchase Commitment [Line Items]
Farm lease acreage				1,000
Price for harvested crop per pound				$ 2
Installment One [Member] | Industrial Hemp Crop Under Cultivation [Member]
Long-term Purchase Commitment [Line Items]
Date for rent payable				Nov. 15, 2018
Installment Two [Member] | Industrial Hemp Crop Under Cultivation [Member]
Long-term Purchase Commitment [Line Items]
Date for rent payable				Dec. 31, 2018
Installment Three [Member] | Industrial Hemp Crop Under Cultivation [Member]
Long-term Purchase Commitment [Line Items]
Date for rent payable				Feb. 15, 2019
Tangiers Global, LLC [Member]
Long-term Purchase Commitment [Line Items]
Line of Credit agreement		$ 2,581,108		$ 2,581,108						$ 10,000,000		$ 10,000,000
Sale of stock | shares				2,907,944
Clinical Trial Agreement [Member] | Installment One [Member]
Long-term Purchase Commitment [Line Items]
Payment made for clinical trial agreement		50,000		$ 50,000				50,000
Clinical Trial Agreement [Member] | Installment Two [Member]
Long-term Purchase Commitment [Line Items]
Payment made for clinical trial agreement		51,182		51,182				51,182
Clinical Trial Agreement [Member] | Installment Three [Member]
Long-term Purchase Commitment [Line Items]
Payment made for clinical trial agreement		51,182		51,182				51,182
Clinical Trial Agreement [Member] | Installment Four [Member]
Long-term Purchase Commitment [Line Items]
Payment made for clinical trial agreement		$ 51,182		$ 51,182				51,182
Consulting Agreement [Member]
Long-term Purchase Commitment [Line Items]
Agreement, term	12 months
Warrant term	5 years
Initial payment	$ 7,500
Shares issued for agreement | shares	250,000
Common stock, price per share | $ / shares	$ 0.18
Consultancy Agreement [Member]
Long-term Purchase Commitment [Line Items]
Expenses recognized								$ 156,630	$ 394,215

COMMITMENTS AND CONTINGENCIES85

COMMITMENTS AND CONTINGENCIES (Summary of Consolidated statements of operations expense) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Cash paid to consultant	$ 379,579	$ 215,386	$ 642,825	$ 456,200	$ 878,257	$ 643,913
Consultant [Member]
Cash paid to consultant					30,000	15,000
Fair value of shares of common stock issued to consultant					27,297	62,781
Fair value of warrants issued to consultant					99,333	319,419
Total contract expenses					$ 156,630	$ 397,200

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Aug. 03, 2018	Jun. 30, 2018	Jun. 29, 2018	Jun. 25, 2018
PTI [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Percentage of ownership	95.00%
Stock Options [Member]
Subsequent Event [Line Items]
Awarded stock options			$ 14,195,000	$ 6,000,000
Stock Options [Member] | Minimum [Member]
Subsequent Event [Line Items]
Exercise price			$ 0.705	$ 1.08
Stock Options [Member] | Maximum [Member]
Subsequent Event [Line Items]
Exercise price			$ 0.58	$ 0.58
Tangiers Global, LLC [Member]
Subsequent Event [Line Items]
Line of Credit agreement		$ 1,833,026
Sale of stock		3,401,719
IND [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Committed expense	$ 300,000